

HHS Public Access

Author manuscript *Mol Cell*. Author manuscript; available in PMC 2023 November 17.

Published in final edited form as:

Mol Cell. 2022 November 17; 82(22): 4353-4367.e6. doi:10.1016/j.molcel.2022.09.030.

PAM binding ensures orientational integration during Cas4-Cas1-Cas2 mediated CRISPR adaptation

Yukti Dhingra¹, Shravanti K. Suresh¹, Puneet Juneja², Dipali G. Sashital^{1,*}

¹Roy J. Carver Department of Biochemistry, Biophysics, & Molecular Biology, Iowa State University, Ames, IA, USA

²Cryo-EM Facility, Office of Biotechnology, Iowa State University, Ames, IA, USA

SUMMARY

Adaptation in CRISPR-Cas systems immunizes bacteria and archaea against mobile genetic elements. In many DNA-targeting systems, the Cas4-Cas1-Cas2 complex is required for selection and processing of DNA segments containing PAM sequences, prior to integration of these "prespacer" substrates as spacers in the CRISPR array. We determined cryo-EM structures of the Cas4-Cas1-Cas2 adaptation complex from the type I-C system that encodes standalone Cas1 and Cas4 proteins. The structures reveal how Cas4 specifically reads out bases within the PAM sequence and how interactions with both Cas1 and Cas2 activate Cas4 endonuclease activity. The Cas4-PAM interaction ensures tight binding between the adaptation complex and the prespacer, significantly enhancing integration of the non-PAM end into the CRISPR array and ensuring correct spacer orientation. Corroborated with our biochemical results, Cas4-Cas1-Cas2 structures with substrates representing various stages of CRISPR adaptation reveal a temporally resolved mechanism for maturation and integration of functional spacers into the CRISPR array.

eTOC blurb

Dhingra et. al use cryo-electron microscopy and biochemistry to understand the mechanism of Cas4-Cas1-Cas2 mediated CRISPR adaptation in the type I-C system. Four structures with various DNA substrates elaborate how the complex clears checkpoints of PAM cleavage and directional spacer insertion into the CRISPR array.

Correspondance: sashital@iastate.edu.

^{*}Lead Contact

AUTHOR CONTRIBUTIONS

Y.D. performed protein purification, complex reconstitution, and grid preparation. Y.D. and P.J. performed grid screening for cryo-EM data collection. P.J. collected the cryo-EM data. Y.D. performed the cryo-EM data processing with P.J. and D.G.S. contributing. D.G.S. built the atomic models. D.G.S and Y.D. refined the models. Y.D. performed all the cleavage assays. S.K.S. performed exonuclease trimming and integration assays. Y.D., S.K.S. and D.G.S analyzed and interpreted the biochemical results, wrote, and edited the manuscript. D.G.S supervised the research and secured funding.

DECLARATION OF INTERESTS

The authors have no financial competing interests to declare. D.G.S. is a member of the Molecular Cell advisory board.

Publisher's Disclaimer: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract



INTRODUCTION

CRISPR (clustered regularly interspersed palindromic repeats) arrays and Cas (CRISPR associated) proteins constitute adaptive and heritable immune systems that rely on molecular recordings of pathogen invasion, enabling rapid and specific response to future infections (Barrangou et al., 2007; Brouns et al., 2008; Marraffini and Sontheimer, 2008). Adaptation is achieved through the integration of small fragments called spacers acquired from invasive nucleic acids (Jackson et al., 2017; Lee and Sashital, 2022). These spacers provide the basis for RNA-guided interference leading to degradation of the foreign nucleic acid upon subsequent exposure (Marraffini, 2015). The CRISPR locus consists of a leader sequence followed by direct repeats interspersed with the acquired spacers, with addition of new spacers occurring almost invariably at the junction of the leader and the first repeat (Arslan et al., 2014; Bolotin et al., 2005; Mojica et al., 2005; Nuñez et al., 2015a, 2015b; Pourcel et al., 2005; Rollie et al., 2015; Yosef et al., 2012).

Target binding and degradation of the invading nucleic acids is preceded by recognition of the PAM (protospacer adjacent motif) located adjacent to the target sequence (Mojica et al., 2009; Redding et al., 2015; Sashital et al., 2012; Semenova et al., 2011; Sternberg et al., 2014; Xue et al., 2017). Because PAM recognition is required for interference, spacers acquired during adaptation must be selected from "prespacers" that contain a PAM

sequence (Hu et al., 2021; Wang et al., 2015; Xiao et al., 2017). Importantly, the PAM is not incorporated into the CRISPR array, preventing "self"-targeting by the interference machinery and necessitating precise removal of the PAM before integration. Integration must take place in a polarized fashion with the non-PAM end and PAM end inserted at the leader-repeat junction on the plus strand and the repeat-spacer junction on the minus strand, respectively, to ensure generation of a crRNA complementary to the target (Jackson et al., 2017; Lee and Sashital, 2022).

Adaptation is mediated by the Cas1-Cas2 integration complex. Cas1 and Cas2 proteins form a heterohexameric complex with two distal Cas1 dimers flanking a Cas2 dimer (Fagerlund et al., 2017; Hu et al., 2021; Lee et al., 2019a; Nuñez et al., 2014; Rollins et al., 2017; Xiao et al., 2017). While cas1 and cas2 are nearly universally conserved in diverse CRISPR-Cas systems, additional factors are required for adaptation in various sub-types (Makarova et al., 2020). Cas4 is the most common ancillary protein involved in adaptation, encoded by type I, II, and V CRISPR-Cas systems (Hudaiberdiev et al., 2017). While Cas4 usually exists as a standalone protein, some systems (type I-G, V-B) encode Cas4/1 fusion proteins, providing evidence of a role for Cas4 in adaptation. In vivo studies have demonstrated that Cas4 is essential for efficient spacer acquisition (Li et al., 2014), ensuring acquisition of spacers with correct PAM sequences (Almendros et al., 2019; Dixit et al., 2021; Kieper et al., 2018, 2021; Zhang et al., 2012) and in the correct orientation (Shiimori et al., 2018). Our previous in vitro studies of the type I-C system from Alkalihalobacillus halodurans (previously Bacillus halodurans) revealed that Cas4 acts as an endonuclease and cleaves specifically and precisely upstream of PAM sequences within 3' overhangs of prespacers (Lee et al., 2018, 2019a). Cas4 forms a higher order complex with Cas1-Cas2 in the presence of a dsDNA substrate, and is only activated as an endonuclease within this complex (Lee et al., 2019a). Recent cryo-electron microscopy (cryo-EM) structures of an adaptation complex from the type I-G system demonstrated that Cas4/1 fusion proteins enable polarized integration through activation of Cas4 cleavage following the first integration event into the CRISPR array (Hu et al., 2021). However, it remains unclear how systems with standalone Cas4 and Cas1 proteins activate Cas4 as an endonuclease for PAM cleavage and enable polarized integration of new spacers.

Here we used cryo-EM to solve high resolution structures of the type I-C Cas4-Cas1-Cas2 complex in the presence of multiple substrates designed to mimic different stages of prespacer processing and integration. Our structural and biochemical results reveal how Cas4 recognizes the PAM with high specificity and sequesters the overhang away from the Cas1 active site. Flexible binding of Cas4 at the non-PAM end slows down trimming by non-specific exonucleases. Unlike in the type I-G Cas4/1 fusion-containing system, we do not observe enhanced endonuclease activation of standalone Cas4 following integration of the non-PAM end. Instead, tight binding of Cas4 to the PAM end of the prespacer and delayed PAM cleavage ensures insertion of the spacer in the correct orientation. Overall, this work demonstrates how Cas4-Cas1-Cas2 achieves processing and integration of functional spacers in the type I-C system.

RESULTS

Cryo-EM structure of the Cas4-Cas1-Cas2 complex

We previously showed in the *A. halodurans* type I-C system that Cas4 is required for prespacer processing precisely upstream of the PAM (Lee et al., 2018, 2019a) (Figure 1A–C). Efficient prespacer processing requires both Cas1 and Cas2, and is dependent on the Cas4 active site, but not on the Cas1 active site (Figure 1C). To investigate how Cas4 is activated within this complex, we solved a 3.4 Å structure of the type I-C Cas4-Cas1-Cas2-prespacer complex using cryo-EM (Figures 1D, S1A, S1C, S1H and S2). We initially reconstituted a complex bound to a prespacer substrate comprising a 22-base pair (bp) duplex with unprocessed 15 nucleotide (nt) 3' overhangs, each containing the 5'-GAA-3' PAM sequence beginning at the seventh position of the overhangs (Figures 1E and S1A–C). Consistent with our previous negative stain reconstruction and the recent cryo-EM structure of the type I-G Cas4/1-Cas2 complex (Hu et al., 2021; Lee et al., 2019a), the cryo-EM structure reveals the typical butterfly shape of Cas1-Cas2. Two Cas1 dimers flank a Cas2 dimer in the middle and a single Cas4 subunit is associated with the wing tip on one end of each Cas1 dimer, resulting in a stoichiometry of Cas4₂:Cas1₄:Cas2₂ (Figures 1D and 1E).

Cryo-EM density for the Cas4 subunits was sufficiently high resolution to build a structural model for a type I-C Cas4 protein using an AlphaFold predicted structural model for guidance (Figure S3A) (Jumper et al., 2021; Mirdita et al., 2022; Varadi et al., 2022). Type I-C Cas4 adopts an overall fold similar to previously determined structures of type I-A, I-B and I-G Cas4 proteins (Hu et al., 2021; Lemak et al., 2013, 2014). The C-terminus of type I-C Cas4 extends further than in the other structures, adopting an α-helix (Figures 1E and S3B–C). While the Cas4 subunits mostly interact with the active subunits of Cas1, the Cas4 C-terminal helix mediates an additional interaction with the inactive Cas1 subunit that does not catalyze the transesterification reaction (Figure S3C). The N-terminus of type I-C Cas4 is located on the opposite side of the protein in comparison to type I-A and I-B, but in a similar location to type I-G (Figure S3B). The N-terminus of Cas4 fits into a positively charged groove near the Cas1 active site, potentially blocking access to a prespacer overhang in the presence of Cas4 (Figure S3D). Consistently, our previous biochemical results indicated that Cas4 prevents premature integration of unprocessed prespacers by Cas1 (Lee et al., 2018).

The cryo-EM map contains continuous density for the single-stranded overhang through the Cas4 active site (Figure 1F). Conserved active site residues D82 and E108 are in proximity of a coordinated Mn^{2+} ion that is positioned to enable cleavage upstream of the 5'-G₂₉-A₃₀-A₃₁-3' PAM sequence (Figures 1F and 1G). While the three residues of the DEK RecB motif (D82, E108 and K110) are positioned similarly to a recent AdnAB structure (Jia et al., 2019), a conserved histidine (H47) that was observed to coordinate divalent ions in both AdnAB and the type I-G Cas4/1 structures (Hu et al., 2021; Jia et al., 2019), is unambiguously pointed away from the Mn²⁺ ion in the type I-C structure (Figure 1G). In addition, density for the scissile phosphate is consistent with an intact phosphodiester bond. Together, these observations suggest that the Cas4 active site structure was captured in an inactive conformation and that cleavage did not occur during complex preparation,

potentially due to the formation of the complex on ice, at a suboptimal temperature for cleavage.

Activation of Cas4 endonuclease activity

While type I-A and I-B Cas4 proteins have been demonstrated to have nonspecific nuclease activities in the absence of Cas1 and Cas2 (Dixit et al., 2021; Lemak et al., 2013, 2014), type I-C Cas4 functions as a sequence specific endonuclease that is only activated in the presence of Cas1 and Cas2 (Lee et al., 2018) (Figure 1C). A striking feature of the type I-C Cas4 structure is a C-terminal extension that ends with the C-terminal helix. This extended C-terminus is common among type I-C Cas4 proteins, but not observed in most other Cas4 sequences, based on comparison of known Cas4 structures (Figure S3B) and multiple sequence alignment of non-redundant Cas4 protein sequences from Cas4-containing CRISPR-Cas subtypes (Figure 2B, Supplemental Data 1). We initially hypothesized that the type I-C Cas4 C-terminal helix may act as an auto-inhibitory domain, accounting for differences in nuclease activities from type I-A and I-B Cas4 enzymes. However, deletion of the Cas4 C-terminal helix (Cth) did not result in activation of Cas4 as a nuclease in the absence of Cas1 and Cas2 (Figure S4A).

We next hypothesized that interactions between Cas4 and Cas1 or Cas2 may result in Cas4 activation. Besides interacting with Cas1, Cas4 also interacts with Cas2 via its α 4 that forms close contacts with α 2 of Cas2 (Figure 2C), similar to an interaction observed in the type I-G Cas4/1-Cas2 structure. Notably, the trajectory of the substrate DNA passes through a narrow hole created, in part, by Cas4 α 4, suggesting that the position of this helix is important for accommodation of the DNA. Together with Cas4-Cas1 interactions, these interactions may explain why Cas4 cleavage activation requires both Cas1 and Cas2 (Figure 1C).

To determine the importance of these interactions for Cas4 cleavage, we tested prespacer cleavage by the Cas4 C-terminal helix deletion (Cth) construct and a Cas2 a2 mutant with Thr46, Thr49, Leu53, Thr56 and Ser57 residues participating in the Cas4-Cas2 interface substituted with alanine (Figures 2D, S4). Cleavage activity was severely diminished upon deletion of the C-terminal helix. In contrast, Cas2 a2 substitutions did not have a substantial effect on cleavage, potentially due to the relatively conservative mutations of threonine or serine to alanine. Interestingly, a combination of the Cas2 a2 substitutions and Cas4 Cth lead to severe loss in cleavage activity of Cas4. It is possible that this loss of cleavage activity is due to a decrease in Cas4 affinity for the Cas1-Cas2 complex, a loss of important interactions that serve to activate Cas4 nuclease activity, or a combination of the two. We performed cleavage using the two mutants either alone or in combination at increasing Cas4 concentration with limited Cas1-Cas2 concentrations to determine whether the observed cleavage defect was independent of Cas4 concentration (Figures S4B and S4C). We did not observe statistically significant differences in cleavage activity at increasing Cas4 variant concentrations, suggesting that Cas4 cleavage is impaired even when Cas4 concentration is saturating. Overall, the additive cleavage defects of these Cas4 variants suggests that interactions with both Cas1 and Cas2 are important for activating Cas4 as an endonuclease.

PAM recognition by Cas4

Cas4 recognizes a GAA PAM sequence positioned within a tight groove that guides the single-stranded overhang through the RecB nuclease domain (Figure 3A). Within the PAM, the two adenine bases adopt a syn conformation, with rotation of the N-glycosidic bond resulting in placement of the adenine bases above the deoxyribose. Polar and nonpolar residues including Asn37, Thr40, Glu119, Gln123, Leu195 and Ile28 aid in shape recognition of the PAM nucleotides and formation of the tight PAM recognition channel (Figure 3B). Each nucleotide of the PAM potentially participates in hydrogen bonding interactions (Figures 3B and 3C). The first nucleotide of the PAM, G29, is in proximity of polar residues His17 and Gln44, with potential formation of a hydrogen bond between His17 and N7 of the G29 purine ring. The second nucleotide of the PAM, A30, is recognized by Ser194 that forms two potential hydrogen bonds with N6 and N7 of the purine ring respectively (Figures 3B and 3C). The PAM is further specified by the last nucleotide A31 that forms two bidentate interactions, which is facilitated by the syn conformation of the adenine base. N1 and N6 of the adenine are in proximity to form hydrogen bonds with Gln16 and N7 and N6 with Gln24 (Figures 3B and 3C). Two hydrophobic residues, Phe20 and Trp34, sit across the phosphodiester backbone. Phe20 is placed after A31 and Trp34 lies between G29 and A30 (Figures 3B and 3C), providing stabilizing stacking interactions for the two purine bases that would be minimized in case of pyrimidines.

To test the importance of these interactions on PAM recognition and prespacer processing, we introduced alanine substitution at each of these potential interacting residues (Figure 3D). All substitutions ablated cleavage activity, with the exception of Q44A and S194A, which only partially reduced cleavage. Gln44 is located within helix α 4, on the opposite face of the helix that interacts with helix a 2 of Cas2 (Figure 2C). The minimal defect in cleavage for the Q44A substitution suggests that Gln44 is not involved in PAM recognition but potentially facilitates widening of the PAM recognition channel to allow correct positioning of the PAM. Partial reduction in cleavage with S194A further indicates that shape recognition mediated by neighboring residues, rather than hydrogen bonding, plays the major role in recognition of the second nucleotide of PAM, A30 (Figure 3D). Additionally, we performed saturation mutagenesis to validate the importance of single nucleotides in the PAM sequence (Figure 3E). We observed that cleavage is severely compromised when we replaced the first or second nucleotides of the PAM, G29 or A30, and is completely lost when the last nucleotide of the PAM A31 is changed. Together, these results strongly suggest that the bidentate recognition of A31 by Gln16 and Gln24 is essential for specific PAM recognition by Cas4 (Figure 3C-E).

We compared the PAM recognition motifs for type I-C Cas4-Cas1-Cas2 and type I-G Cas4/1-Cas2 complexes (Hu et al., 2021) to understand differences that might affect the overall specificity of the two systems (Figure 3F). The type I-G adaptation complex lacks specificity at the first position of the PAM, recognizing a 5'-NAA-3' PAM sequence, in contrast to the relative specificity for 5'-GAA-3' observed in type I-C (Almendros et al., 2019; Rao et al., 2017). Consistently, the equivalent residue to His17 in I-C is Glu18 in I-G, which is positioned slightly further from the guanine, but could form a hydrogen bond with N1 of either adenine in the PAM upon protonation of the Glu18 carboxylate (Figure 3F).

Similarly, Trp34, which stacks with the guanine in I-C, is replaced with Phe35 in I-G. This substitution may decrease the stacking interaction energy and possibly reduce specificity for a purine at this position of the PAM in I-G (Rutledge et al., 2006).

Recognition of the third position of the PAM also differs between the two structures. While the adenine in the type I-C structure is stabilized in the syn conformation based on a dual-bidentate interaction with Gln16 and Gln24, the type I-G structure positions the equivalent adenine in an anti conformation, enabling the aforementioned potential hydrogen bonding interaction with Glu18 (Figure 3F). Gln16 of I-C is substituted with Asn17 in I-G. This shorter side chain and slightly further positioning prevents recognition of the adenine via specific hydrogen bonding interactions that are observed in type I-C. Gln24 of I-C is substituted with Leu25 in I-G, which mediates van der Waals contacts with the adenine for shape readout but does not enable specific hydrogen bonding. Overall, these differences suggest that Cas4 may confer higher specificity for a GAA PAM in the type I-C system.

Cas4-Cas1-Cas2 complex specifies the length of the prespacer duplex and overhang

In addition to the 22 bp duplex prespacer, we also solved the cryo-EM structure of a complex with a 24 bp duplex with 3' overhangs containing PAMs starting at the sixth position (Figures S1A, S1B, S1G, S1H and S5A–G). The reconstruction has weaker density for one of the active Cas1 subunits, while density for the partner subunit is stronger, suggesting conformational heterogeneity (Figures S5H and S5I). Additionally, density for the prespacer corresponds to a 22 bp duplex, suggesting unwinding of the last base pair at either end of the duplex, and creating a 6 nt overhang up to the PAM sequence (Figure S5I). A conserved tyrosine in Cas1 plays a role in defining the duplex in potential prespacers in other systems like type I-E (Nuñez et al., 2015a). Tyr49 is positioned similarly in the Cas4-Cas1-Cas2 structure, suggesting a similar role for duplex definition in type I-C systems (Figure 4A).

The two Cas4-Cas1-Cas2 structures indicate that a 6 nt single-stranded overhang is necessary to stretch the PAM from the end of the duplex to the Cas4 PAM recognition motif (Figure 1F, S5I). We previously observed that prespacer substrates with 4 nt between the duplex and the PAM were cleaved as efficiently as prespacers with 6 nt between the duplex and the PAM (Lee et al., 2019a). Combined with our structural observations, these results imply that Cas4-Cas1-Cas2 can unwind multiple base pairs to access the single-stranded PAM. To test this further, we analyzed Cas4-dependent cleavage of two sets of prespacer substrates. One set of substrates contains a 26 bp duplex with 2 nt between the end of the duplex and the PAM. To determine the effect of unwinding, we varied the G-C content of the terminal 4 base pairs. We compared these to another set of substrates containing a 22 bp duplex with 6 nt between the end of the duplex and the PAM, and varying number of Gs at the first four positions after the duplex (Figure 4B). While we observe comparable cleavage of the latter set with 22 bp duplex substrates with varying Gs, we observed a linear correlation between the number of terminal A-T base pairs and the amount of cleavage for the 26 bp duplex substrates, suggesting that substrates that can be more readily unwound due to a higher number of A-T pairs result in better PAM accessibility (Figures 4C and 4D).

Together, these results indicate that the Cas4-Cas1-Cas2 complex can unwind the ends of duplexes to allow Cas4 to gain access to the single stranded PAM region.

Cas4 slows down exonucleolytic trimming of the non-PAM end

Cas4 cleavage is highly sequence specific and only processes the PAM end of the prespacer (Lee et al., 2019a). The non-PAM end of the prespacer is likely trimmed by cellular non-specific exonucleases, similar to other type I systems where DnaQ-like exonucleases have been implicated in prespacer processing (Hu et al., 2021; Kieper et al., 2021; Kim et al., 2020; Ramachandran et al., 2020). To simulate the Cas4-Cas1-Cas2 complex before and after trimming of the non-PAM end, we solved cryo-EM structures of Cas4-Cas1-Cas2 bound to either a PAM/NoPAM (Figures 5A, S1A, S1B, S1D, S1H and S6) substrate or a PAM/processed substrate (Figures 5B, S1A, S1B, S1E, S1H and S7). Both substrates contained a 22-bp duplex with one 15-nt overhang containing a PAM and either another 15-nt overhang without a PAM (PAM/NoPAM substrate) (Figure 5A and S1B), or a 6-nt overhang simulating a processed non-PAM end (PAM/processed substrate) (Figure 5B and S1B).

Single-particle analysis of these complexes yielded 3.9 Å and 3.3 Å reconstructions for the PAM/NoPAM and PAM/processed complexes, respectively (Figures 5A and 5B). For both maps, we observed only partial density for one of the two Cas4 subunits, resulting in asymmetrical reconstructions that we have previously observed by negative stain (Lee et al., 2019a). Because Cas4 specifically binds to a PAM containing sequence, we concluded that the lobe with stronger density for Cas4 is the PAM end and the lobe with partial density is the non-PAM end of the substrate. We did not observe any significant differences in Cas4 conformation on the PAM end between the PAM/PAM and the PAM/NoPAM or PAM/processed complexes.

On the non-PAM end, we observed stronger density for a second Cas4 subunit when the longer 3'-overhang was present in the PAM/NoPAM substrate (Figure 5A). In contrast, the PAM/processed complex nearly completely lacked Cas4 density (Figure 5B). In the PAM/ NoPAM reconstruction, density is present for the iron-sulfur cluster domain and C-terminal helix (Figure 5A). However, the density is weaker in regions that do not directly contact one of the Cas1 subunits. Notably, we observed a complete lack of density for $\alpha 4$ of Cas4 that typically interacts with a Cas2 $\alpha 2$ on the non-PAM end (Figure 5C). This lack of density suggests that $\alpha 4$ is conformationally flexible and does not interact stably with Cas2 $\alpha 2$ in the absence of PAM binding.

Similar to the PAM end, density for single-stranded DNA on the non-PAM end is traceable from the end of the duplex toward the Cas4 active site when the 15 nt overhang was present in the PAM/NoPAM substrate. However, no density is present past residue 28 of the DNA, consistent with a lack of stabilizing interactions with Cas4 in the absence of a PAM (Figure S8A). In the presence of the 6 nt overhang in the PAM/processed substrate, we could trace only 2 nt of ssDNA overhang density (Figure S8B). Overall, these structures suggest that longer DNA overhangs are necessary to anchor Cas4 to the Cas1-Cas2 complex, although Cas4 associates most stably when a PAM is present in the overhang.

Page 9

Based on these structural observations, we hypothesized that Cas4 remains partially associated with Cas1-Cas2 in the presence of long 3'-overhangs and may affect trimming of the non-PAM end by cellular exonucleases. To test this, we used a commercially available DnaQ-like exonuclease, ExoT, to trim the non-PAM end of the PAM/NoPAM substrate in the presence of Cas1-Cas2 or Cas4-Cas1-Cas2 and a DNA substrate containing a leader-repeat-spacer to mimic a CRISPR array for integration (Figures 5D and S8C). ExoT trimming of the non-PAM end of the Cas1-Cas2-bound prespacer produced products of similar length to a pre-processed prespacer control, although trimming was slowed substantially in the presence of Cas4 (Figure 5D). The trimmed products were integrated into the CRISPR DNA, producing an integration product of similar size to the pre-processed control, with a slight enhancement of integration observed in the presence of Cas4. Overall, these results suggest that unstable association of Cas4 at the non-PAM end offers partial protection from exonucleolytic trimming, slowing down processing of the non-PAM end.

Cas4-Cas1-Cas2 mediates polarized integration

Functional spacer acquisition requires integration of the non-PAM end of the prespacer at the leader-repeat junction on the positive strand (hereafter leader site) and the PAM end at the repeat-spacer junction on the negative strand (hereafter spacer site) (Figure S8C). Importantly, Cas4 association with Cas1-Cas2 is mutually exclusive with prespacer integration into the CRISPR array, as observed previously in our negative stain reconstructions and in type I-G cryo-EM structures (Hu et al., 2021; Lee et al., 2019a). Cas4 dissociates from the non-PAM end, allowing integration at the leader site. A recent 5.8 Å structure of type I-G Cas4/1-Cas2 bound to a half-site intermediate (HSI) showed that the Cas4 domain remains associated with the PAM end of the prespacer following this integration event (Hu et al., 2021). The structure suggested that the adjacent Cas1 domain interacts with the repeat, although the low resolution of the reconstruction limited interpretation of this interaction.

To determine how the repeat interacts within the type I-C adaptation complex, we solved a 4 Å cryo-EM structure of the Cas4-Cas1-Cas2 complex bound to a half-site intermediate (Figures 6A, 6B, S1A, S1B, S1F, S1H and S9). We used the Cas1 active site mutant E166A to prevent disintegration of the prespacer strand integrated at the leader site of the HSI mimic. Strong density for the CRISPR DNA could be observed in the reconstruction (Figures 6A and 6B). The DNA helix bends sharply near the leader-repeat junction with another slight bend near the Cas4-Cas2 interface. The repeat spans the side of the complex opposite to the prespacer duplex. Unlike in the type I-G structure, where the repeat appears to contact the inactive Cas1 domain of the Cas4/1 subunit, in the type I-C structure, the repeat contacts the C-terminal helix of Cas4 (Figure 6C). Specifically, two arginine residues Arg207 and Arg211 in the Cas4 C-terminal helix point directly at the terminal sequence of the repeat, interdigitating within the minor groove of the repeat end of the CRISPR (Figure 6C). This may suggest a role of Cas4 in correctly orienting the complex onto the CRISPR array, positioning the PAM end of the prespacer close to the repeat-spacer site for integration following PAM cleavage and Cas4 dissociation.

In the type I-G system, PAM cleavage by the Cas4 domain of Cas4/1 is activated following integration of the prespacer at the leader site, potentially due to the interaction between the repeat and the inactive Cas1 domain (Hu et al., 2021). Cleavage is followed by integration of the PAM end at the spacer site. Overall, this mechanism ensures insertion of a correctly oriented spacer. However, we have previously observed that type I-C Cas4 cleavage activity is not altered in the presence of a CRISPR array (Lee et al., 2019a), suggesting that Cas4 is not activated through interactions with the CRISPR following integration of the non-PAM end. To further investigate whether type I-C Cas4 is activated following half-site integration, we compared Cas4 cleavage of the PAM end within an HSI substrate with cleavage of the PAM/NoPAM and PAM/processed substrates (Figures 6D and 6E). Similar to our previous results, we did not observe any significant differences in the fraction of substrate cleaved at various time points between the substrates, suggesting that Cas4 processing is not dependent on the integration of the non-PAM strand at the leader site. To test whether interactions between the Cas4 C-terminal helix and the repeat affect PAM-end processing following leader-site integration, we tested a quadruple mutant of Cas4 (Q) with the two C-terminal arginine residues and two nearby lysine residues (Lys206 and Lys210) substituted with alanine (Figures 6D and 6E). Mutations of these residues had no effect on PAM cleavage within the HSI substrate. Overall, these results strongly suggest that Cas4 is not activated through interactions with the repeat following non-PAM integration in the type I-C adaptation complex, in contrast to the type I-G system.

Cas4 enhances integration of the prespacer non-PAM end

As noted above, in the exonuclease trimming assays, we observed slightly more integration in the presence of Cas4, despite observing slower exonucleolytic cleavage in this condition (Figure 5D). This led us to hypothesize that Cas4 may enhance integration at the leader site. To measure this effect more precisely, we used a PAM/processed substrate with the processed strand radiolabeled to measure integration of this strand at the leader site in the absence and presence of Cas4 (Figures 6F and S8C). We observed substantial enhancement of integration at multiple temperatures in the presence of Cas4 (Figures 6F and G), while Cas4 had no detectable effect on Cas1 disintegration activity (Figure S10). These observations suggest an additional role for Cas4 within the Cas4-Cas1-Cas2 complex in enhancing integration at the leader site.

We next tested whether enhanced integration is an effect of PAM cleavage in the presence of Cas4 or interactions between the Cas4 C-terminal helix and the repeat. However, neither a Cas4 active site mutant nor the quadruple Cas4 C-terminal mutant (Q) substantially affected the enhancement of integration (Figure 6F). Similarly, substrates containing phosphorothioate substitutions at the scissile phosphate that prevent PAM cleavage still displayed enhanced integration in the presence of Cas4 (Figure S11). Notably, a substrate containing processed 6-nt overhangs on both ends was not integrated well either in the presence or absence of Cas4 (Figure S11B). Overall, these results strongly suggest that Cas4 enhances integration of the processed end at the leader site due to its tight binding to a PAM-containing substrate rather than its PAM cleavage activity or its interaction with the CRISPR repeat.

DISCUSSION

Our structural and biochemical results provide a kinetic model for prespacer processing and integration by the type I-C Cas4-Cas1-Cas2 complex (Figure 7). During prespacer capture, Cas4 is essential for binding prespacers containing a PAM sequence (Figure 7A). These prespacers may be single-stranded or double-stranded fragments of degradation products, potentially of the AddAB complex (Ivan i -Bace et al., 2015; Kim et al., 2020; Levy et al., 2015; Modell et al., 2017). While Cas4 stably binds to the PAM end, it remains flexible on the non-PAM end, slowing trimming of this end to the proper length by cellular exonucleases (Figures 7A and 7B). Nevertheless, trimming of the non-PAM end gives rise to an asymmetric substrate based on the slow kinetics of Cas4 PAM cleavage. Following trimming, Cas4 dissociates from the non-PAM end (Figures 7B and 7C). Tight binding of Cas4 at the PAM end increases the likelihood of integration of the non-PAM end at the leader site, enabling rapid formation of a half-site integration intermediate after exonucleolytic trimming (Figures 7C and 7D). Following PAM cleavage, Cas4 dissociates from the complex, allowing the mature PAM end to be integrated at the spacer site resulting in insertion of a polarized and functional spacer (Figures 7E and 7F).

We demonstrate that interactions between the C-terminal helix of Cas4 and the inactive Cas1 subunit combined with interactions between Cas4 α 4 and Cas2 α 2 are necessary for efficient cleavage. The Cas4 C-terminal helix extends from the iron-sulfur cluster domain, which contains several of the PAM-recognition residues. Thus, docking of Cas4 to Cas1 via the C-terminal helix may position the iron-sulfur cluster domain correctly for PAM recognition. The position of Cas4 α 4 is also important to allow ssDNA to pass through the Cas4 active site. Our cryo-EM reconstruction of the PAM/NoPAM complex suggests that this helix is conformationally flexible in the absence of PAM binding. Notably, the α 4 and C-terminal helices are the most mobile structural elements in the five highest ranked AlphaFold models (Figure S3A). We propose that interactions formed by the Cas4 active site and stable recognition via a properly positioned iron-sulfur domain.

Our results indicate that Cas4 enhances prespacer integration by Cas1-Cas2 at the leader site. In native type I-A and I-B systems, deletion of Cas4 substantially reduces spacer acquisition (Li et al., 2014; Shiimori et al., 2018), although this reduction is less pronounced in a heterologous type I-D system (Kieper et al., 2018), potentially due to overexpression of Cas1-Cas2. Combined with our *in vitro* observations, these results suggest that Cas4 is necessary not only for prespacer selection and processing, but also for optimal integration of spacers in the CRISPR array. The observed enhancement is likely due to higher affinity of prespacer binding in the presence of Cas4 due to specific PAM interactions. Importantly, enhanced integration relies on delayed Cas4 cleavage activity, as Cas4 does not enhance integration of a fully processed prespacer. Thus, the slow kinetics of Cas4 cleavage enables asymmetric prespacer processing and enhanced leader site integration of the non-PAM end, contributing to the directional integration of the prespacer.

Recent structural and biochemical studies of the type I-G Cas4/1-Cas2 complex indicated that interactions between Cas4/1 and the CRISPR activates the Cas4 domain following half-

site integration (Hu et al., 2021). However, we have not observed activation of type I-C Cas4 under many different conditions, suggesting that type I-G and I-C systems use alternative mechanisms for Cas4 activation. Importantly, we do not observe efficient cleavage activity of Cas4 at reduced temperatures (e.g. 37 °C), either for prespacer or HSI substrates. This suggests the possibility of another factor that might activate type I-C Cas4 for PAM cleavage at mesophilic temperatures. In type I-E and I-F systems, host factor IHF binds and bends the CRISPR leader DNA to enhance Cas1-Cas2 binding and allow efficient integration to occur (Fagerlund et al., 2017; Nuñez et al., 2016; Wright et al., 2017; Yoganand et al., 2017). It remains unknown if systems that contain additional factors like Cas4 require such host factors. However, various conserved upstream sequence elements have been identified in specific CRISPR-Cas subtypes, including type I-C, and may be important for spacer acquisition as observed in type I-E and I-F (Santiago-Frangos et al., 2021). Further investigation is required to determine whether Cas4-Cas1-Cas2 or a host factor interacts with upstream sequence elements in the CRISPR leader to activate Cas4 and ensure integration fidelity.

Delayed PAM processing is a common feature in type I systems to achieve directional spacer integration, although the exact mechanisms by which PAM processing is controlled remains unclear. In type I-E, which lacks Cas4, protection of the PAM end by the Cas1 C-terminal tail leads to delayed exonucleolytic trimming of the PAM end, ensuring integration of the non-PAM end at the leader site (Kim et al., 2020; Ramachandran et al., 2020). However, it is not known how the PAM is released from Cas1 and processed prior to the second integration event. Similarly it remains unclear how two distinct Cas4 proteins control prespacer directionality in type I-A (Shiimori et al., 2021), or whether an additional factor is required to activate Cas4 in type I-C. Future studies will be necessary to fully elucidate these mechanisms.

Limitations of the Study

Our results suggest that interactions with both Cas1 and Cas2 are necessary for activation of Cas4 as an endonuclease. We observed cleavage defects for Cth and Cth/ α 2 at saturating concentrations of Cas4 (Figure 2D). However, it is also likely that these variations in protein sequence alter the affinity of Cas4 for the Cas1-Cas2 complex. A direct quantitative measurement of the dissociation constants for WT Cas4 and Cth Cas4 with Cas1-Cas2 or Cas1-Cas2(α 2) is challenging due to instability of the purified proteins. We attempted isothermal titration calorimetry to measure the binding affinity of WT or Cth Cas4 with Cas1, but our results were inconclusive due to precipitation of both proteins over the course of the measurement.

Our results show that Cas4 increases the efficiency of integration by Cas1-Cas2. Combined with the intimate interaction between Cas4 and the PAM, these results suggest that enhanced integration is due to higher affinity for a PAM-containing prespacer. However, we have been unable to develop an assay to directly determine the binding affinity of Cas4-Cas1-Cas2 for DNA substrates and therefore cannot rule out the possibility that other factors, including Cas4 interactions with the CRISPR substrate, may play a role in this enhancement.

We did not observe enhancement of type I-C Cas4 prespacer cleavage activity following half-site integration, but cannot rule out the possibility that such activation occurs. It is possible that additional DNA sequences or host protein factors are necessary to observe complete Cas4 activation.

STAR METHODS

RESOURCE AVAILABILITY

Lead Contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dipali Sashital (sashital@iastate.edu).

Materials availability—Plasmids and reagents used in this study are available from the Lead Contact Dipali Sashital without restriction.

Data and code availability

- The atomic models for Cas4-Cas1-Cas2 complexes with different substrates have been deposited in the Protein Data bank (PDB) under accession numbers 8D3L (PAM/PAM), 8D3Q (PAM/NoPAM), 8D3M (PAM/Processed) and 8D3P (HSI) and are publicly available as of the date of publication. The cryo-EM density maps described in this work have been deposited to Electron Microscopy Data Bank (EMDB) under accession numbers EMD-27159 (PAM/PAM), EMD-27162 (PAM/NoPAM), EMD-27160 (PAM/Processed), EMD-27161 (HSI) and EMD-27769 (PAM/PAM 24 bp duplex) and are publicly available as of the date of publication. All gel images are available on Mendeley Data at https://doi.org/10.17632/yk6bgzh6st.1 and are publicly available as of the date of publication.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODELS AND SUBJECT DETAILS

Escherichia coli BL21 (DE3)—*E. coli* BL21 (DE3) cells were used for protein production of Cas1 and Cas2 for in vitro experiments. Cells were grown in LB medium supplemented with 50 mg/ml kanamycin.

Escherichia coli C41 (DE3)—*E. coli* C41 (DE3) cells were used for protein production of Cas4 with pSUF for in vitro experiments. Cells were grown in 2xYT medium supplemented with 100 mg/ml ampicillin and 34 mg/ml chloramphenicol.

Escherichia coli NEB 5-alpha—*E. coli* NEB 5-alpha cells were used for cloning of plasmids. Cells were grown in LB medium supplemented with 50 mg/mL kanamycin or 100 mg/mL ampicillin or 34 mg/ml of chloramphenicol.

METHOD DETAILS

Cloning, protein expression and purification.—Previously described constructs for Cas1, Cas2 and Cas4 expression were used to express and purify the individual proteins (Lee et al., 2018, 2019a). For co-expression with Cas4, sufABCDSE genes were amplified from pSUF plasmid and cloned into pACYC using Gibson assembly. All primers used for cloning various constructs have been listed in Table S1.

Cas1 and Cas2 were overexpressed in E. coli BL21(DE3) and grown at 37 °C to 0.5 $OD_{600 \text{ nm}}$ in LB media, followed by overnight induction at 17 °C with 1 mM IPTG. Cas4 was co-expressed with sufABCDSE-pACYC in E. coli C41 cells and grown to an OD_{600 nm} of 0.5 in 2XTY media. Cells were induced with 1 mM IPTG and the cultures were supplemented with 100 mg of ferric citrate, ferrous sulfate, ferrous ammonium sulfate and L-cysteine at the time of induction. 1000x solutions for ferrous sulfate, ferrous ammonium sulfate and a 100x solution for ferric citrate were prepared and filtered prior to induction. Cultures were grown overnight at 17 °C. For all protein purifications, cells were harvested by centrifuging at 4000 rpm for 30 minutes, resuspended in Ni-NTA buffer (50 mM Na₂HPO₄ pH 8.0, 500 mM NaCl, 5% glycerol, 2 mM DTT) supplemented with 10 mM imidazole (pH 8.0) and 100 mM PMSF, and lysed using a sonicator (Branson UltrasonicsTM SonifierTM). The lysate was centrifuged at 18000 rpm for 30 minutes (Beckman Coulter Avanti J-E) and the supernatant was used for further purification. All proteins were initially purified using HisPur Ni-NTA affinity resin (Thermo Fisher Scientific) using Ni-NTA buffer supplemented with 25 mM imidazole during wash and 250 mM imidazole during elution. His6-MBP-Cas1 and His6-MBP-Cas2 were dialyzed against Ni-NTA buffer and His6-MBP was cleaved using TEV protease overnight at 4 °C. The cleaved protein was purified with subtractive Ni-NTA. Flow through and wash fractions were analyzed by SDS-PAGE. The cleanest fractions were pooled. In case of MBP contamination following subtractive Ni-NTA, the protein was dialyzed in buffer A (20 mM HEPES pH 7.5, 100 mM KCl, 5% glycerol and 2 mM DTT) for 3 hours at 4 °C. Dialyzed protein was loaded on a 5 mL HiTrap Heparin column (GE Healthcare) equilibrated with buffer A to remove the MBP, and Cas1 or Cas2 was eluted using a gradient of buffer B (20 mM HEPES pH7.5, 2M KCl, 5% glycerol, 2 mM DTT). The protein was concentrated and further purified on a Superdex 75 16/600 GL column (GE Healthcare), in a size exclusion buffer (20 mM HEPES pH 7.5, 100 mM KCl, 5% glycerol and 2 mM DTT).

To reduce the possibility of protein purification tags on Cas1 or Cas4 interfering with activation of Cas4 in the presence of a half-site intermediate, we redesigned our constructs to His₆-SUMO-Cas1 and Cas4 with His₆ on the C-terminus. For His₆-SUMO-Cas1, Ni-NTA purified protein was dialyzed overnight against Ni-NTA buffer and the SUMO tag was cleaved using Ulp1 protease. The cleaved protein was purified with subtractive Ni-NTA followed by purification on a Superdex 75 16/600 GL column (GE Healthcare), in a size exclusion buffer (20 mM HEPES pH 7.5, 100 mM KCl, 5% glycerol and 2 mM DTT). For His₆-Cas4 with His tag on N- or C- terminus, NiNTA purification was directly followed by further purification on Superdex 200 16/600 GL column (GE Healthcare), in a higher salt size exclusion buffer (20mM HEPES pH 7.5, 500 mM KCl, 5% glycerol and 2 mM DTT).

ExoT was obtained from New England Biolabs.

Complex formation.—For Cas4-Cas1-Cas2 complex formation, DNA substrates were pre-annealed and purified using native 10% PAGE. For assembling complexes with various DNA substrates, 20 μ M Cas1, 10 μ M Cas2, 30 μ M Cas4, and 10 μ M substrate DNA were mixed (final approximate ratio of 2:1:3:1) in a final volume of 500 μ L in complex formation buffer (20 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol, 2 mM DTT, and 2 mM MnCl₂) and incubated on ice for 45 min. Cas4-Cas1-Cas2-DNA complexes were purified using a Superdex 75 10/300 GL column (GE Healthcare) in complex formation buffer. Peak fractions were visualized by SDS-PAGE and the fractions containing all three proteins were pooled and concentrated to 8–10 μ M, flash frozen in liquid nitrogen and stored at –80°C.

Cryo EM grid preparation and data acquisition.—3 µl of ~ 1.5 µM (0.75 mg/ml) of the complex was applied to freshly glow discharged quantifoil 300 mesh R 1.2/1.3 grids (EMS) and plunge frozen into liquid ethane using a Thermo Fisher Vitrobot Mark IV with conditions of 4 °C, 100% humidity, blot force 3, and a 3 second blot time. Grids were clipped and transferred to Thermo Fisher Scientific 200 kV Glacios microscope equipped with a K3 Direct Electron Detector (DED) at the Iowa State University cryo-EM facility. 45 frame movies were recorded in super-resolution counting mode with pixel size of 0.44865 Å. Total electron dose was 50.5 e⁻ Å². Movies were collected using SerialEM (Mastronarde, 2005) with single image per hole strategy and a defocus range of 1.5–3.5 µm.

Cryo-EM data processing.—All data processing was performed in cryoSPARC v3.1.0 and v3.2.0 (Punjani et al., 2017). Following motion correction and CTF estimation, blob picking was performed with a circular blob of minimum and maximum particle diameter of 100 Å and 300 Å respectively for the first data set. Particles were then subjected to multiple rounds of 2D classifications with a 200 Å circular mask diameter and resulting classes were used for template picking with a particle diameter of 300 Å. Template picked particles were extracted with a box size of 384 and binned to a box size of 128 for processing until homogenous refinements. Extracted particles were subjected to iterative 2D classifications. Selected 2D classes were then used to build an ab initio model. All particles were refined using homogenous refinement with the ab initio model. These were then used for heterogeneous refinements into 3-5 classes depending on the number of particles in the dataset. Homogenous and Non-uniform refinements (Punjani, Zhang and Fleet, 2020) were further used with CTF refinement of particles performed before the refinement step or on the fly during the refinement. Figures S2, S5, S6, S7 and S9 illustrate the processing pipeline for PAM/PAM, PAM/PAM with 24 bp duplex, PAM/NoPAM, PAM/Proc and HSI maps respectively. Data collection details and validation statistics for all reconstructions have been listed in Table 1. All maps were visualized using UCSF Chimera during processing (Pettersen et al., 2004). Figures were prepared in Chimera X (Goddard et al., 2018).

Modeling, Refinement, and analysis.—AlphaFold (Jumper et al., 2021;; Varadi et al., 2022) models for Cas1 and Cas4 predicted using ColabFold version 1.0 (Mirdita et al., 2022) and the crystal structure for Cas2 (Nam et al., 2012) were used as templates to facilitate building models for the three proteins in *Coot* (Emsley et al., 2010). AlphaFold

models shown in Figure S3 were predicted using AlphaFold version 2.1.1. DNA for the prespacer (PAM/PAM, PAM/NoPAM, PAM/Proc models) and the CRISPR array (HSI model) were built de novo in Coot. Multiple rounds of model refinement were performed in Phenix.real_space_refine (Liebschner et al., 2019) with secondary structure, base pairs, stacking pairs and Fe₄S₄ cluster restrains. Molprobity (Williams et al., 2018) was used to guide iterative refinements in Phenix with manual adjustments performed in Coot between subsequent rounds of refinements. Adjustments to the DNA sequence and removal of bases or protein chains for specific models were done in Coot followed by refinements in Phenix. All figures with density maps or models or both were prepared using ChimeraX (Goddard et al., 2018).

DNA substrate preparation.—All oligonucleotides were synthesized by Integrated DNA Technologies. Sequences of all DNA substrates are shown in Table S2. All DNA substrates were first purified using 10% PAGE with 8 M urea and 1X TBE and ethanol precipitation. Purified prespacers were labeled with $[\gamma^{-32}P]$ -ATP (PerkinElmer) and T4 polynucleotide kinase (NEB) at the 5['] end. Excess ATP was removed using Microspin G-25 columns (GE Healthcare).

Prespacer processing assays.—For preparing duplex substrates, a 5' radiolabeled strand was annealed an unlabeled complementary strand in a 1:2 ratio (25 nM radiolabeled strand and 50 nM unlabeled strand) in cleavage buffer (20 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol, 4 mM DTT, 4 mM MnCl₂,). For processing assays with the half-site intermediate, the substrate was prepared by annealing the labelled strand with twice as much of each of the unlabeled DNA strands. The hybridization reactions were incubated at 95 °C for 3 min followed by slow cooling to room temperature.

Cas1, Cas2 and Cas4 were premixed on ice, substrate was added at a final concentration of 1–5 nM and the reactions were incubated at 65 °C for 30 min unless indicated otherwise. A final concentration of 250 nM Cas1, 250 nM Cas2 and 500 nM Cas4 was used unless otherwise indicated. Under these conditions, Cas1 concentration is limiting, minimizing formation of Cas1-Cas2 or Cas4-Cas1 sub-complexes. The final concentration of Cas4-Cas1-Cas2 is expected to be ~62.5 nM based on the presence of four Cas1 subunits in the complex. Reactions were quenched with 2X RNA loading dye (95% formamide, 0.01% SDS, 0.01% bromophenol blue, 0.01% xylene cyanol supplemented with 25 mM of EDTA) and heated at 95 °C for 5 min. Samples were run on 10% urea-PAGE. The gels were dried and imaged using phosphor screens on a Typhoon imager.

For quantification, the intensity of bands was measured by densitometry using ImageJ (Schneider, Rasband and Eliceiri, 2012). The fraction cleaved was calculated by dividing the product band by the sum of both bands. The values from three or four replicates were averaged, error is reported as standard deviation between the replicates.

For comparison of PAM/NoPAM, PAM/Proc and HSI substrates (Figure 6D), the reactions were performed at a variety of temperatures and Cas1, Cas2 and Cas4 concentrations. We did not observe differences in activity regardless of protein concentration, and we did not observe processing activity at mesophilic temperatures for any substrate tested.

Concentrations of 100 nM Cas1, 100 nM Cas2 and 50 nM Cas4 at a temperature of 65 °C were used for the experiment shown in Figure 6D. These conditions were selected to minimize cleavage of the prespacer in an attempt to observe increased cleavage of the HSI substrate. Cas1 purified using both His₆-MBP-Cas1, which retains additional GAGS N-terminal amino acids following TEV cleavage, and His₆-SUMO-Cas1 constructs, which does not contain any additional sequence on the N- or C-terminus, were tested and the assays done with His₆-SUMO-Cas1 are reported in Figure 6D–E. Cas4 purified with both N- and C-terminal His tags were tested and the cleavage assays reported in Figure 6D–E were done with C-terminal His tag.

All oligonucleotides used for the assays are listed in Table S2.

Exonuclease trimming assays and integration assays using PAM/Proc

substrates.—Reactions were performed in buffer containing 20 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol, 10 mM MgCl₂, 5 mM MnCl₂ and 2 mM DTT. Purified Cas1 (100 nM), Cas2 (50 nM), and Cas4 (50 nM) were pre-incubated with 5 nM 5'-radiolabelled prespacer DNA on ice for 15 min. Reduced concentrations of Cas1 and Cas2 maximized the effect of Cas4 on integration efficiency, likely due to increased affinity of Cas1-Cas2 for the prespacer at higher concentrations. For the exonuclease trimming assays, ExoT was added at a concentration of 1 U/ μ L, and the reactions were further incubated at 37 °C for 5 min, 15 min and 30 min. To observe integration, 1 µM of the linear mini-CRISPR array (consisting of a 20 bp leader segment, a 32 bp repeat sequence and a 5 bp spacer sequence, shown in Table S2) was added to the reaction prior to incubation at 37°C. For the exonuclease trimming assays, the mini-CRISPR DNA contained phosphorothioate groups at the 3' ends to prevent degradation by the exonuclease. For the time course reactions, a master mix was prepared and an aliquot of 10 µL was taken at each time point. Reactions were quenched with 2X loading dye at the indicated time points. The samples were denatured at 95 °C for 5 minutes and analyzed by 10% urea-PAGE, as described above. Oligonucleotides used for the assays have been listed in Table S2.

QUANTIFICATION AND STATISTICAL ANALYSIS

Three or four replicates were performed for specific *in vitro* experiments and representative gel images were shown. For quantification, the intensity of bands was measured by densitometry using ImageJ. Error bars indicate standard deviation for all plotted data.

Data S1. Multiple sequence alignments for Cas4 sequences from various

CRISPR subtypes. Related to Figure 2—This data is available on Mendeley Data at https://doi.org/10.17632/yk6bgzh6st.1. We compared non-redundant Cas4 protein sequences from Cas4-containing CRISPR subtypes using multiple sequence alignments. To do this, we used the phylogenetic tree generated and described in by the authors in Hudaiberdiev et al., 2017 to get a list of organisms from various CRISPR subtypes that encode Cas4. We then confirmed the presence of Cas4 associated with the specific subtype from randomly selected organisms. These confirmed Cas4 sequences from specific subtypes were then aligned using Clustal Omega. All Cas4 sequences from the type I-C system have an extra C-terminal

region that is not found in all sequences analyzed from the other subtypes. This dataset is available in a zip folder and includes the following:

- 1. CLUSTAL Omega multiple sequence alignment files for multiple non-redundant Cas4 sequences from CRISPR subtypes I-A, I-B, I-C, I-D, II-B, V-A and V-F, and Cas4b/Csa1 sequences from Type I-A systems.
- 2. FASTA files for the sequences used in the multiple sequence alignments.
- **3.** Excel files with details on Uniprot/GenBank IDs of protein sequences used and organisms that encode these Cas4 proteins.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We thank Dr. Eric Underbakke and the lab for the generous gift of pET-His-SUMO vector and Ulp1 protease. We thank Dr. Yang Yang and Dr. Katherine Berry for helpful discussions on model building with cryo-EM reconstructions; Dr. Scott Nelson and Dr. Baoyu (Stone) Chen for helpful discussions on experimental design. We thank members of the ResearchIT group at Iowa State University for computational support; Tracey Stewart and Roy J Carver High Resolution Microscopy Facility for technical assistance with negative stain EM screening of samples used in cryo-EM. We thank all the members of the Sashital Lab for helpful input throughout the course of this project. All data used for cryo-EM reconstructions reported in this work was collected at the Iowa State University Cryo-EM Facility, which was established through a grant from the Roy J. Carver Charitable Trust (Muscatine, IA). Data was collected for the Cas4-Cas1-Cas2 PAM/PAM construct at the National Center for CryoEM Access and Training (NCCAT) and the Simons Electron Microscopy Center located at the New York Structural Biology Center, supported by the NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129539,) and by grants from the Simons Foundation (SF349247) and NY State Assembly. This work was supported by an NIH R01 grant (GM115874) and NIH R35 grant (GM140876) to DGS.

REFERENCES

- Almendros C, Nobrega FL, McKenzie RE, and Brouns SJJ (2019). Cas4-Cas1 fusions drive efficient PAM selection and control CRISPR adaptation. Nucleic Acids Res. 47, 5223–5230. 10.1093/nar/ gkz217. [PubMed: 30937444]
- Arslan Z, Hermanns V, Wurm R, Wagner R, and Pul Ü (2014). Detection and characterization of spacer integration intermediates in type I-E CRISPR-Cas system. Nucleic Acids Res. 42, 7884– 7893. 10.1093/nar/gku510. [PubMed: 24920831]
- Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, and Horvath P (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science (80-.). 315. 10.1126/science.1138140.
- Bolotin A, Quinquis B, Sorokin A, and Dusko Ehrlich S (2005). Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151, 2551–2561. 10.1099/mic.0.28048-0. [PubMed: 16079334]
- Brouns SJJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJH, Snijders APL, Dickman MJ, Makarova KS, Koonin EV, and Van Der Oost J (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. Science (80-.). 321. 10.1126/science.1159689.
- Dixit B, Anand V, Hussain MS, and Kumar M (2021). The CRISPR-associated Cas4 protein from Leptospira interrogans demonstrate versatile nuclease activity. Curr. Res. Microb. Sci 2. 10.1016/ j.crmicr.2021.100040.
- Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010). Features and development of Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 486–501. 10.1107/S0907444910007493. [PubMed: 20383002]

- Fagerlund RD, Wilkinson ME, Klykov O, Barendregt A, Pearce FG, Kieper SN, Maxwell HWR, Capolupo A, Heck AJR, Krause KL, et al. (2017). Spacer capture and integration by a type I-F Cas1-Cas2–3 CRISPR adaptation complex. Proc. Natl. Acad. Sci. U. S. A. 114, E5122–E5128. 10.1073/pnas.1618421114. [PubMed: 28611213]
- Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, and Ferrin TE (2018). UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25. 10.1002/pro.3235. [PubMed: 28710774]
- Hu C, Almendros C, Nam KH, Costa AR, Vink JNA, Haagsma AC, Bagde SR, Brouns SJJ, and Ke A (2021). Mechanism for Cas4-assisted directional spacer acquisition in CRISPR–Cas. Nature 598, 515–520. 10.1038/s41586-021-03951-z. [PubMed: 34588691]
- Hudaiberdiev S, Shmakov S, Wolf YI, Terns MP, Makarova KS, and Koonin EV (2017). Phylogenomics of Cas4 family nucleases. BMC Evol. Biol. 17. 10.1186/s12862-017-1081-1.
- Ivan i -Bace I, Cass SD, Wearne SJ, and Bolt EL (2015). Different genome stability proteins underpin primed and Naïve adaptation in E. Coli CRISPR-Cas immunity. Nucleic Acids Res. 43, 10821– 10830. 10.1093/nar/gkv1213. [PubMed: 26578567]
- Jackson SA, McKenzie RE, Fagerlund RD, Kieper SN, Fineran PC, and Brouns SJJ (2017). CRISPR-Cas: Adapting to change. Science (80-.). 356. 10.1126/science.aal5056.
- Jia N, Unciuleac MC, Xue C, Greene EC, Patel DJ, and Shuman S (2019). Structures and singlemolecule analysis of bacterial motor nuclease AdnAB illuminate the mechanism of DNA double-strand break resection. Proc. Natl. Acad. Sci. U. S. A. 116, 24507–24516. 10.1073/ pnas.1913546116. [PubMed: 31740608]
- Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589. 10.1038/s41586-021-03819-2. [PubMed: 34265844]
- Kieper SN, Almendros C, Behler J, McKenzie RE, Nobrega FL, Haagsma AC, Vink JNA, Hess WR, and Brouns SJJ (2018). Cas4 Facilitates PAM-Compatible Spacer Selection during CRISPR Adaptation. Cell Rep. 22, 3377–3384. 10.1016/j.celrep.2018.02.103. [PubMed: 29590607]
- Kieper SN, Almendros C, Haagsma AC, Barendregt A, Heck AJR, and Brouns SJJ (2021). Cas4-Cas1 Is a Protospacer Adjacent Motif-Processing Factor Mediating Half-Site Spacer Integration during CRISPR Adaptation. Cris. J 4. 10.1089/crispr.2021.0011.
- Kim S, Loeff L, Colombo S, Jergic S, Brouns SJJ, and Joo C (2020). Selective loading and processing of prespacers for precise CRISPR adaptation. Nature 579, 141–145. 10.1038/s41586-020-2018-1. [PubMed: 32076262]
- Lee H, and Sashital DG (2022). Creating memories: molecular mechanisms of CRISPR adaptation. Trends Biochem. Sci. 10.1016/j.tibs.2022.02.004.
- Lee H, Zhou Y, Taylor DW, and Sashital DG (2018). Cas4-Dependent Prespacer Processing Ensures High-Fidelity Programming of CRISPR Arrays. Mol. Cell 70, 48–59.e5. 10.1016/ j.molcel.2018.03.003. [PubMed: 29602742]
- Lee H, Dhingra Y, and Sashital DG (2019a). The Cas4-Cas1-Cas2 complex mediates precise prespacer processing during CRISPR adaptation. Elife 8. 10.7554/eLife.44248.
- Lee H, Dhingra Y, Sashital DG, and Carver RJ (2019b). The Cas4-Cas1-Cas2 complex mediates precise prespacer processing during CRISPR adaptation. 10.7554/eLife.44248.001.
- Lemak S, Beloglazova N, Nocek B, Skarina T, Flick R, Brown G, Popovic A, Joachimiak A, Savchenko A, and Yakunin AF (2013). Toroidal structure and DNA cleavage by the CRISPRassociated [4Fe-4S] cluster containing Cas4 nuclease SSO0001 from sulfolobus solfataricus. J. Am. Chem. Soc. 135, 17476–17487. 10.1021/ja408729b. [PubMed: 24171432]
- Lemak S, Nocek B, Beloglazova N, Skarina T, Flick R, Brown G, Joachimiak A, Savchenko A, and Yakunin AF (2014). The CRISPR-associated Cas4 protein Pcal 0546 from Pyrobaculum calidifontis contains a [2Fe-2S] cluster: Crystal structure and nuclease activity. Nucleic Acids Res. 42, 11144–11155. 10.1093/nar/gku797. [PubMed: 25200083]
- Levy A, Goren MG, Yosef I, Auster O, Manor M, Amitai G, Edgar R, Qimron U, and Sorek R (2015). CRISPR adaptation biases explain preference for acquisition of foreign DNA. Nature 520, 505–510. 10.1038/nature14302. [PubMed: 25874675]

- Li M, Wang R, Zhao D, and Xiang H (2014). Adaptation of the Haloarcula hispanica CRISPR-Cas system to a purified virus strictly requires a priming process. Nucleic Acids Res. 42, 2483–2492. 10.1093/nar/gkt1154. [PubMed: 24265226]
- Liebschner D, Afonine PV, Baker ML, Bunkoczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ, et al. (2019). Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta Crystallogr. Sect. D Struct. Biol. 75, 861–877. 10.1107/S2059798319011471. [PubMed: 31588918]
- Makarova KS, Wolf YI, Iranzo J, Shmakov SA, Alkhnbashi OS, Brouns SJJ, Charpentier E, Cheng D, Haft DH, Horvath P, et al. (2020). Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat. Rev. Microbiol. 18, 67–83. 10.1038/s41579-019-0299-x. [PubMed: 31857715]
- Marraffini LA (2015). CRISPR-Cas immunity in prokaryotes. Nature 526, 55–61. 10.1038/ nature15386. [PubMed: 26432244]
- Marraffini LA, and Sontheimer EJ (2008). CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science (80-.). 322. 10.1126/science.1165771.
- Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, and Steinegger M (2022). ColabFold: making protein folding accessible to all. Nat. Methods 10.1038/s41592-022-01488-1.
- Modell JW, Jiang W, and Marraffini LA (2017). CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Nature 544, 101–104. 10.1038/nature21719. [PubMed: 28355179]
- Mojica FJM, Díez-Villaseñor C, García-Martínez J, and Soria E (2005). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60, 174– 182. 10.1007/s00239-004-0046-3. [PubMed: 15791728]
- Mojica FJM, Díez-Villaseñor C, García-Martínez J, and Almendros C (2009). Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733–740. 10.1099/mic.0.023960-0. [PubMed: 19246744]
- Nam KH, Ding F, Haitjema C, Huang Q, DeLisa MP, and Ke A (2012). Double-stranded endonuclease activity in Bacillus halodurans clustered regularly interspaced short palindromic repeats (CRISPR)-associated Cas2 protein. J. Biol. Chem. 287, 35943–35952. 10.1074/jbc.M112.382598. [PubMed: 22942283]
- Nuñez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, and Doudna JA (2014). Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity. Nat. Struct. Mol. Biol. 21, 528–534. 10.1038/nsmb.2820. [PubMed: 24793649]
- Nuñez JK, Harrington LB, Kranzusch PJ, Engelman AN, and Doudna JA (2015a). Foreign DNA capture during CRISPR-Cas adaptive immunity. Nature 527, 535–538. 10.1038/nature15760. [PubMed: 26503043]
- Nuñez JK, Lee ASY, Engelman A, and Doudna JA (2015b). Integrase-mediated spacer acquisition during CRISPR-Cas adaptive immunity. Nature 519, 193–198. 10.1038/nature14237. [PubMed: 25707795]
- Nuñez JK, Bai L, Harrington LB, Hinder TL, and Doudna JA (2016). CRISPR Immunological Memory Requires a Host Factor for Specificity. Mol. Cell 62, 824–833. 10.1016/ j.molcel.2016.04.027. [PubMed: 27211867]
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004). UCSF Chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 25. 10.1002/jcc.20084.
- Pourcel C, Salvignol G, and Vergnaud G (2005). CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151, 653–663. 10.1099/mic.0.27437-0. [PubMed: 15758212]
- Punjani A, Rubinstein JL, Fleet DJ, and Brubaker MA (2017). CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14. 10.1038/nmeth.4169.
- Punjani A, Zhang H, and Fleet DJ (2020). Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17. 10.1038/s41592-020-00990-8.
- Ramachandran A, Summerville L, Learn BA, DeBell L, and Bailey S (2020). Processing and integration of functionally oriented prespacers in the Escherichia coli CRISPR system depends

on bacterial host exonucleases. J. Biol. Chem. 295, 3403–3414. 10.1074/jbc.RA119.012196. [PubMed: 31914418]

- Rao C, Chin D, and Ensminger AW (2017). Priming in a permissive type I-C CRISPR-Cas system reveals distinct dynamics of spacer acquisition and loss. RNA 23. 10.1261/rna.062083.117.
- Redding S, Sternberg SH, Marshall M, Gibb B, Bhat P, Guegler CK, Wiedenheft B, Doudna JA, and Greene EC (2015). Surveillance and Processing of Foreign DNA by the Escherichia coli CRISPR-Cas System. Cell 163. 10.1016/j.cell.2015.10.003.
- Rollie C, Schneider S, Brinkmann AS, Bolt EL, and White MF (2015). Intrinsic sequence specificity of the Cas1 integrase directs new spacer acquisition. Elife 4. 10.7554/eLife.08716.
- Rollins MCF, Chowdhury S, Carter J, Golden SM, Wilkinson RA, Bondy-Denomy J, Lander GC, and Wiedenheft B (2017). Cas1 and the Csy complex are opposing regulators of Cas2/3 nuclease activity. Proc. Natl. Acad. Sci. U. S. A. 114, E5113–E5121. 10.1073/pnas.1616395114. [PubMed: 28438998]
- Rutledge LR, Campbell-Verduyn LS, Hunter KC, and Wetmore SD (2006). Characterization of nucleobase-amino acid stacking interactions utilized by a DNA repair enzyme. J. Phys. Chem. B 110. 10.1021/jp061939v.
- Santiago-Frangos A, Buyukyoruk M, Wiegand T, Krishna P, and Wiedenheft B (2021). Distribution and phasing of sequence motifs that facilitate CRISPR adaptation. Curr. Biol. 31. 10.1016/j.cub.2021.05.068.
- Sashital DG, Wiedenheft B, and Doudna JA (2012). Mechanism of Foreign DNA Selection in a Bacterial Adaptive Immune System. Mol. Cell 46, 606–615. 10.1016/j.molcel.2012.03.020. [PubMed: 22521690]
- Schneider CA, Rasband WS, and Eliceiri KW (2012). Image to ImageJ: 25 years of image analysis. Nature methods. Nat. Methods 9.
- Semenova E, Jore MM, Datsenko KA, Semenova A, Westra ER, Wanner B, Van Der Oost J, Brouns SJJ, and Severinov K (2011). Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl. Acad. Sci. U. S. A. 108. 10.1073/pnas.1104144108.
- Shiimori M, Garrett SC, Graveley BR, and Terns MP (2018). Cas4 Nucleases Define the PAM, Length, and Orientation of DNA Fragments Integrated at CRISPR Loci. Mol. Cell 70, 814–824.e6. 10.1016/j.molcel.2018.05.002. [PubMed: 29883605]
- Sternberg SH, Redding S, Jinek M, Greene EC, and Doudna JA (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62–67. 10.1038/nature13011. [PubMed: 24476820]
- Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, et al. (2022). AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50. 10.1093/nar/gkab1061.
- Wang J, Li J, Zhao H, Sheng G, Wang M, Yin M, and Wang Y (2015). Structural and Mechanistic Basis of PAM-Dependent Spacer Acquisition in CRISPR-Cas Systems. Cell 163, 840–853. 10.1016/j.cell.2015.10.008. [PubMed: 26478180]
- Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, Verma V, Keedy DA, Hintze BJ, Chen VB, et al. (2018). MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27. 10.1002/pro.3330.
- Wright AV, Liu JJ, Knott GJ, Doxzen KW, Nogales E, and Doudna JA (2017). Structures of the CRISPR genome integration complex. Science (80-.). 357, 1113–1118. 10.1126/science.aa00679.
- Xiao Y, Ng S, Hyun Nam K, and Ke A (2017). How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration. Nature 550, 137–141. 10.1038/nature24020. [PubMed: 28869593]
- Xue C, Zhu Y, Zhang X, Shin YK, and Sashital DG (2017). Real-Time Observation of Target Search by the CRISPR Surveillance Complex Cascade. Cell Rep. 21, 3717–3727. 10.1016/ j.celrep.2017.11.110. [PubMed: 29281822]
- Yoganand KNR, Sivathanu R, Nimkar S, and Anand B (2017). Asymmetric positioning of Cas1–2 complex and Integration Host Factor induced DNA bending guide the unidirectional homing

of protospacer in CRISPR-Cas type I-E system. Nucleic Acids Res. 45, 367–381. 10.1093/nar/gkw1151. [PubMed: 27899566]

- Yosef I, Goren MG, and Qimron U (2012). Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli. Nucleic Acids Res. 40, 5569–5576. 10.1093/nar/gks216. [PubMed: 22402487]
- Zhang J, Kasciukovic T, and White MF (2012). The CRISPR Associated Protein Cas4 Is a 5' to 3' DNA Exonuclease with an Iron-Sulfur Cluster. PLoS One 7. 10.1371/journal.pone.0047232.

Highlights

- Cas4-Cas1-Cas2 cryo-EM structures reveal type I-C spacer acquisition mechanism
- Type I-C Cas4 contains a C-terminal helix important for Cas4 activation
- Cas4 specifically recognizes and sequesters PAM-end of prespacer substrates
- Cas4 enhances first prespacer integration event in the CRISPR

Dhingra et al.

Page 24



Figure 1, also see Figure S1, S2 and S3: Cryo-EM structure of the type I-C Cas4-Cas1-Cas2 complex $% \mathcal{A} = \mathcal{A}$

(A) Overview of *cas* genes and CRISPR locus of type I-C system in *Alkalihalobacillus halodurans. cas* genes are shown as arrows with the gene products involved in adaptation or interference indicated. Spacers and repeats are shown as colored rectangles and black diamonds respectively.

(B) Schematic of prespacer cleavage assay. Cleavage site upstream of PAM is indicated with an arrow, radiolabel is indicated with an orange star.

(C) Cleavage assay with substrate shown in (B). E indicates a Cas1 active site mutant E166A or Cas4 active site mutant E108A. Sizes for substrate (37 nt) and product (28 nt) are indicated.

(D) Cryo-EM reconstruction of Cas4-Cas1-Cas2 complex with PAM/PAM substrate (Figure S1B). Subunits are labeled and colored as follows: dark blue, active Cas1 subunits; light sky

blue, inactive Cas1 subunits; tan, Cas2 dimer; salmon, Cas4; dark gray and white, prespacer strands; yellow, PAM.

(E) Structural model of the Cas4-Cas1-Cas2 PAM/PAM complex, colored as in (D).

(F) Close up view of cryo-EM density (white) for single-stranded overhang. PAM residues are shown in yellow. Active site residues of Cas1 and Cas4 are labeled.

(G) Close-up of Cas4 active site. The DEK motif residues (D82, E108 and K110) and His47 are shown as sticks. Cryo-EM density is shown for the coordinated Mn^{2+} ion, portions of Cas4, and the DNA in proximity to the active site.

Dhingra et al.



Figure 2, also see Figure S4: Activation of Cas4 endonuclease activity (A) Side surface view of Cas4-Cas1-Cas2 PAM/PAM complex with C-terminal helix and PAM labeled. Inset shows structural model with transparent surface. Iron-sulfur cluster and PAM are labeled.

(B) Clustal Omega multiple sequence alignment for the C-terminus of representative Cas4 sequences from Cas4-containing CRISPR-Cas systems. 'a' indicates the type I-G sequence, which is a Cas4/1 fusion protein. The sequence was truncated at the end of the Cas4 domain based on structural analysis (Hu et al., 2021). Cas4 sequences were used from the following organisms: *Saccharolobus solfataricus* (I-A); *Pyrobaculum calidifontis* (I-B); *Alkalihalobacillus halodurans* (I-C); *Synechocystis sp.* (I-D); *Geobacter sulfurreducens* (I-G); *Francisella tularensis subsp. novicida* (II-B); *Micrarachaeum acidiphilum* (II-C); *Francisella tularensis subsp. novicida* (V-A); *Uncultured archaeon* (V-F). Type V-B was omitted from the analysis due to the presence of a Cas4/1 fusion, for which the end of the Cas4 domain cannot be precisely determined. Multiple sequence alignments for many non-redundant Cas4 protein sequences from each subtype and details on sequences used is available in Supplemental Data 1.

(C) Surface view of one lobe of the complex highlighting interaction between $\alpha 2$ of Cas2 and $\alpha 4$ of Cas1. The close-up shows the structural model fit in the cryo-EM density for the two helices.

(D) Quantification of fraction cleaved for cleavage assay with individual Cas4 (Cth) or Cas2 α 2 mutant (alanine substitutions of Thr46, Thr49, Leu53, Thr56 and Ser57) or a combination of the two. The assay was performed at final concentrations of 250 nM Cas1, 250 nM Cas2 and 2 μ M Cas4. The data points were fit to a one phase exponential

association. Polyacrylamide gel for the cleavage assay is shown in Figure S4C. The average of three replicates is shown, error bars represent standard deviation.

Dhingra et al.



Figure 3: PAM recognition by Cas4

(A) Surface view of single-stranded overhang travelling to Cas4 PAM recognition pocket.(B) Specific and non-specific interactions between Cas4 residues (labeled in salmon with black outline) and PAM nucleotides (labeled in blue). Potential hydrogen bonds are shown as dashed lines.

(C) Close-up view of potential hydrogen bonds formed by individual PAM nucleotides.

(D) Polyacrylamide gel showing cleavage assay with PAM recognition mutants. The assay was performed with final concentrations of 250 nM Cas1, 250 nM Cas2 and 500 nM Cas4 and quenched at 30 minutes.

(E) Quantification of cleavage assay for saturation mutagenesis of each nucleotide in the PAM sequence, performed as in (D). N indicates the position that was mutated. The average of three replicates is shown, error bars represent standard deviation and the three data points are plotted as dots.

(F) Comparison of I-C and I-G Cas4 showing specific and stacking interactions for PAM recognition.

Dhingra et al.

Page 30



Figure 4, also see Figure S1 and S5: Cas4-Cas1-Cas2 complex specifies the length of the prespacer duplex and overhang

(A) Surface view of Cas4-Cas1-Cas2 PAM/PAM structural model highlighting 22 bp duplex and Tyr49 from both active Cas1 subunits. Close up view of Tyr49 (purple) interaction with the last base pair (green) of the 22 bp duplex of the prespacer is shown.

(B) Panel of substrates used in unwinding and processing assays; 22 bp duplex substrates (6 nt between duplex and 5'-GAA-3' PAM) with varying number of G's at the first 4 nt after the duplex; 26 bp duplex substrates (2 nt between the duplex and 5'-GAA-3' PAM) containing between zero and four GC pairs at the end of the 26 bp duplex. Radiolabel is indicated with a star.

(C) Representative denaturing polyacrylamide gel of cleavage of substrates shown in (B). The assay was performed with final concentrations of 250 nM Cas1, 250 nM Cas2 and 500 nM Cas4 and quenched at 30 minutes. Sizes for substrate (37 nt) and product (28 nt) are indicated.

(D) Quantification of cleavage assay shown in (C). The average of four replicates is shown, error bars represent standard deviation and the four data points are plotted as dots.

Dhingra et al.



Figure 5, also see Figure S1, S6, S7 and S8: Cas4 slows down exonucleolytic trimming of the non-PAM end

(A) Substrate schematic and cryo-EM reconstruction of Cas4-Cas1-Cas2 PAM/NoPAM complex.

(B) Substrate schematic and cryo-EM reconstruction of Cas4-Cas1-Cas2 PAM/processed complex.

(C) Densities for Cas4 at PAM and No-PAM ends of PAM/NoPAM complex shown in (A). PAM is colored in yellow and labeled.

(D) Denaturing polyacrylamide gel of the prespacer trimming and integration assays using ExoT exonuclease. The assay was performed with final concentrations of 100 nM Cas1, 50 nM Cas2 and 50 nM Cas4. The first lane contains a radiolabeled 65 nt ssDNA representative of leader site integration product (also see Figure S8C). Lengths of the 65 nt integration product and the Proc/Proc (28 nt) or PAM/NoPAM (37 nt) substrates are indicated on the left of the gel. Lanes with only substrate are labeled N. All other lanes have Cas1 and Cas2. Presence or absence of Cas4 and ExoT is indicated. Black arrow indicates integration products. Note that ³²P signal is decreased in the second lane due to a loading error.



Figure 6, also see Figure S1, S9, S10 and S11: Cas4-Cas1-Cas2 mediates polarized integration (A) Substrate schematic and cryo-EM reconstruction of Cas4-Cas1-Cas2 HSI complex. Protein subunits and prespacer strands are colored as in Figure 1D. Leader and repeat DNA are colored purple and green, respectively.

(B) Structural model for HSI complex with integration site, PAM, leader, repeat and Cas4 C-terminal helix (Cth) labeled.

(C) Side view of HSI complex with close-up view of Cas4 C-terminal interaction with the repeat DNA.

(D) Representative denaturing polyacrylamide gel of cleavage assay with PAM/NoPAM, PAM/processed (PAM/Proc) and HSI substrates. Wild type Cas4 was used for PAM/ NoPAM, PAM/processed and HSI samples, while the Cas4 repeat-interacting residue mutant (Q; Alanine substitutions of Lys206, Arg207, Lys210 and Arg211) was used for gel on right. The assay was performed with final concentrations of 100 nM Cas1, 100 nM Cas2 and 50 nM Cas4. Radiolabel is indicated with a star. Lanes for samples with only DNA are labeled N, or time points are labeled in minutes.

(E) Quantification for percent cleaved in (D). The average of four replicates is shown, error bars represent standard deviation and the four data points are plotted as dots.

(F) Schematic of integration assay with PAM/Processed (PAM/Proc) substrate. Integration of the processed non-PAM end at the leader site enables polarized integration and results in formation of a 65-nt product. Radiolabel is indicated with an orange star.

(G) Representative denaturing polyacrylamide gels showing integration of the processed end in the absence and presence of WT Cas4, Cas4 active-site mutant (E108A) and Cas4 repeat-interacting residue mutant (Q). The assay was performed with final concentrations of 100 nM Cas1, 50 nM Cas2 and 50 nM Cas4 and quenched at 30 minutes. Lanes with only substrate are labeled N. All other lanes contained Cas1 and Cas2. Presence or absence of Cas4 is indicated. Black arrow indicates integration products.

(H) Quantification of substrate integration in the presence and absence of Cas4 at different temperatures. The average of three replicates is shown, error bars represent standard deviation and the three data points are plotted as dots.



Figure 7: Kinetic model of Cas4-Cas1-Cas2 mediated processing and integration of prespacers

(A) Cas4-Cas1-Cas2 binding to a PAM/NoPAM prespacer.

(B) Rapid trimming of non-PAM end by exonucleases, with Cas4 providing partial protection.

(C) Dissociation of Cas4 from the non-PAM end following trimming.

(D) Association of Cas4-Cas1-Cas2 to the CRISPR array with integration of a mature non-PAM end at the leader-repeat junction.

(E) Cleavage of PAM by Cas4 and dissociation of Cas4, handoff of mature PAM end to Cas1 for integration.

(F) Integration of the mature PAM end at repeat-spacer junction.

Author Manuscript

Table 1:

Data collection parameters for the five reconstructions and refinement statistics for four models described in this study

	PAM/PAM	PAM/NoPAM	PAM/Proc	HSI	PAM/PAM 24bp duplex
Data collection and processing					
Magnification	45000	45000	45000	45000	45000
Voltage (kV)	200	200	200	200	200
Electron exposure (e-/Å ²)	50	50	50	50	50
Defocus range	~1.5 to 3.5				
Pixel size (Å)	0.9063	0.9063	0.9063	0.9063	0.9063
Symmetry imposed	C1	C1	C1	C1	C1
No of movies collected	1571	1506	1554	1947	6960
Final map resolution (Å)	3.46	3.9	3.41	4.3	3.9
FSC threshold	0.143	0.143	0.143	0.143	0.143
Refinement					
B factors (Å ²)					
Protein (max)	95.05	178.17	142.90	185.76	N/A
Protein (mean)	24.22	96.65	73.98	95.89	N/A
RMS Deviations					
Bond lengths (Å)	0.003	0.006	0.005	0.006	N/A
Bond angles (°)	0.617	0.72	0.729	1.018	N/A
Validations					
MolProbity	1.89	2.12	2.06	2.45	N/A
Clashscore	8.83	13.91	11.11	13.78	N/A
Poor rotamers (%)	0.06	0.00	0	2.7	N/A
Model Composition					
Non-hydrogen atoms	17485	17153	15518	17389	N/A
Amino acid residues	2001	1974	1784	1790	N/A
Ligands	4	3	2	2	N/A
Nucleotides	65	60	56	146	N/A
Ramachandran plot					
Favored (%)	93.75	92.38	91.64	90.71	N/A
Allowed (%)	5.99	7.41	8.02	8.67	N/A
Disallowed (%)	0.25	0.20	0.34	0.62	N/A

KEY RESOURCES TABLE

Beterial and virus strainsExclericing SalphaNerglang MagnetSerglangExclericing Salpha ConstructionsSerglangSerglangExclericing Salpha ConstructionsSerglangSerglangExclericing Salpha ConstructionsSerglangSerglangSalpha ConstructionsSerglangSerglangS	REAGENT or RESOURCE	SOURCE	IDENTIFIER
Excherichia coii NES solutionNew England BiolatonCorrestExcherichia coii NEJ (DES) Overcepters CISigmaCalorationChernichia coii NEJ (DES) Overcepters CISigmaNationalParentes And exceptionTermor Fisher Scenie (National Scenario)SigmaSigmaSodium phosphate dibasi heptaphydraeTermor Fisher Scenie (National Scenario)SigmaSigmaSodium phosphate dibasi heptaphydraeTermor Fisher Scenie (National Scenario)SigmaSigmaSodium ChorideTermor Fisher Scenie (National Scenario)SigmaSigmaGlycerolTermor Fisher Scenie (National Scenario)SigmaSigmaGlycerolReflSigmaSigmaSigmaMargenes choride terrationationReflSigmaSigmaMargenes choride terrationationReflSigmaSigmaSigmaReflSigmaSigmaSigmaFormationReflSigmaSi	Bacterial and virus strains	•	•
Exercicle 031921 (DE3)CN271Becherichia coil B121 (DE3) OvercepterS (AIISigmaCM2017Chemicats, perptides, and recombinant proteinsFilterSSigmaSigmaBerBSControllersSigmaSigmaSodium chorides cherptalydrateChernic SigmaSigmaSigmaSodium ChorideControllersSigmaSigmaIndraceControllersSigmaSigmaPotassium ChorideChernic SigmaSigmaSigmaOrgendiaChernic SigmaSigmaSigmaOrgendiaSigmaSigmaSigmaOrgendiaSigmaSigmaSigmaOrgendiaChernic SigmaSigmaSigmaOrgendiaSigmaSigmaSigmaOrgendiaSigmaSigmaSigmaOrgendiaSigmaSigmaSigmaOrgendiaSigmaSigma<	Escherichia coli NEB 5-alpha	New England Biolabs	С2987Н
Exencicle 001910KernoreChemicals pertides, and recombinant proteinsHEFESInfern Seiners#B731Sodium phophate disaic heptahydrateInfern Seiners#S473.Sodium ChorideNarmor Seiners#S473.Sodium ChorideInfern Seiners#S473.IndiazoleNarmor Seiners#S473.Golay ChorideRemor Seiners#S473.Golay ChorideInfern Seiners#S473.GycerolInfern Seiners#S473.GycerolSeiners#S470.Manganes choride tetrahydrateRemor Seiners#S470.PMSFRPI#S430.#S470.Billian blue R-250Remor Seiners#S470.FormaticNarco#S470.Sylee CharageMarco#S470.Sylee Char	Escherichia coli Bl21 (DE3)	New England Biolabs	С2527Н
Chemicals, peptides, and recombinant proteinsHEPESInerno Fisher Scientif4 BP3101Sodium phosphate dibasic heptahydrateInerno Fisher Scientif4 S373-3Sodium ChlorideTherno Fisher Scientif4 S4010IndizoleTherno Fisher Scientif4 S019Potassium ChlorideRP14 P0370-00GlycerolTherno Fisher Scientif4 M37-100Manganes chloride ternahydrateNermo Fisher Scientif4 M37-100Manganes chloride ternahydrateNermo Fisher Scientif4 M37-100Potassium Chlore Actionation ternahydrateNermo Fisher Scientif4 M30-100-100Barlian blae R-250RP14 S12-03-00FormanideNermo Fisher Scientif4 S12-03-00FormanideNermo Fisher Scientif4 S12-13-00SDSNermo Fisher Scientif4 S12-13-00Space Scientific Scient	Escherichia coli Bl21 (DE3) Overexpress C41	Sigma	CMC0017
HEPESThemo Fisher Scientifi#BP3101Sodium phosphate dibasic heptalydrateThermo Fisher Scientifi#S373.3Sodium ChlorideThermo Fisher Scientifi#S64010IndazoleThermo Fisher Scientifi#O3196-500Potassiun ChlorideRP1#P173GlycerolThermo Fisher Scientifi#O3196-500Manganes choride tertalydrateThermo Fisher Scientifi#M87100Manganes choride tertalydrateRP1#P20270-50Brilliant blae R-250RP1#B4300-500EDTAThermo Fisher Scientifi#0319-600FormanideThermo Fisher Scientifi#051-21-30System CyanolRP1#92070-50FormanideThermo Fisher Scientifi#051-21-30System CyanolThermo Fisher Scientifi#051-21-30System CyanolThermo Fisher Scientifi#051-21-30System CyanolAmereco#050-17-11System CyanolThermo Fisher Scientifi#051-21-30System CyanolThermo Fisher Scientifi#051-21-30System CyanolAmereco#050-17-11System CyanolThermo Fisher Scientifi#0512-07-11System CyanolThermo Fisher Scientifi#0512-07-11System CyanolSystem Cyanol#0102-07-11System CyanolFisher Scientific#0102-07-11System CyanolFisher Scientific#0102-07-11System CyanolFisher Scientific#0102-07-11System CyanolFisher Scientific#0102-07-11System Cyanol	Chemicals, peptides, and recombinant proteins		-
Sodium phosphate dibasic heptalydrateThermo Fisher Scientife# \$373.3Sodium ChlorideThermo Fisher Scientife# 64010IndrazoleThermo Fisher Scientife# 2173GlycerolThermo Fisher Scientife# 2173GlycerolThermo Fisher Scientife# 01100-100.0Maganese chloride tetrahydrateThermo Fisher Scientife# M87.100PMSFRPI# 84300.500# 84300.500Brilliant blue R-250RPI# 84300.500EDTAThermo Fisher Scientife# 6319-26FormanideThermo Fisher Scientife# 512-13SDSThermo Fisher Scientife# 512-13SDSNerroe Sisher Scientife# 512-13Yaplen CyanolAmesco# 2650-17-1FornamideNerroe Sisher Scientife# 512-13SDSNerroe Fisher Scientifie# 512-13SDSNerroe Sisher Scientifie# 512-13Yaplen CyanolAmesco# 2650-17-1Fornophenol BueVWR# 115-29-0Luria BrothNerroe Sisher Scientifie# 512-13Yapten CyanolNerroe	HEPES	Thermo Fisher Scientific	# BP3101
Sodium ChlorideFhermo Fisher Scientifie# 54010InidazoleThermo Fisher Scientifie# 03196-500Potassium ChlorideRPI# P2173GlycerolThermo Fisher Scientifie# 03100-100.0Maganes chloride tetrahydrateThermo Fisher Scientifie# 011000-100.0PMSFRPI# P20270-25.0Brilliant blue R-250RPI# 84300-50.0EDTAThermo Fisher Scientifie# 6381-92.0FormanideThermo Fisher Scientifie# 6381-92.0SDSThermo Fisher Scientifie# 512-33.0Sylee CyanolAmeresco# 2650-17.1Bromophenol BlueVWR# 115-39.0Luria BorthYB1202# 115-39.0Luria BorthYB1202# 115-39.0YaptoXPR# 115-39.0YuptoKPI# 50217.1Bromophenol BlueVWR# 115-39.0Luria BorthHERCE# 115-39.0YuptoKPI# 50217.1YuptoKPI# 50217.1YuptoKPI# 50217.1YuptoKPI# 50217.1YuptoKPI# 50217.1YuptoYapto# 50217.1YuptoKPI# 50217.1YuptoKPI# 50217.1YuptoYapto# 50217.1YuptoYapto# 50217.1YuptoYapto# 50217.1YuptoYapto# 50217.1YuptoYapto# 50217.1YuptoYapto# 50217.1YuptoYap	Sodium phosphate dibasic heptahydrate	Thermo Fisher Scientific	# \$373-3
InidazoleFnemo Fisher Scientifi# 30196-500Potassiun ChlorideRPI# 2173GlycerolThermo Fisher Scientifi# 3031-0DTTThermo Fisher Scientifi# 30100-1000Manganese chloride tertahydrateThermo Fisher Scientifi# 30100-1000PMSFRPI# 84300-500Brilliant blue R-250RPI# 84300-500EDTAThermo Fisher Scientifi# 3619-263FormanideThermo Fisher Scientifi# 5712-7SDSThermo Fisher Scientifi# 5712-7SDYThermo Fisher Scientifi# 1512-13Yalen CyanolAmesco# 2650-17-1Stylen CyanolNermo Fisher Scientifi# 1512-13TyponeYano# 2650-17-1Formonibane BlueVWR# 1612-13Yaptone DatuMarcot# 260-17-1Stylen CyanolStartact# 260-17-1Yaptone Sufface# 1612-13# 1512-13Yaptone DatuMarcot# 260-17-1Stylen CyanolStartact# 260-17-1Yaptone DatuMarcot# 260-17-1Yaptone DatuMarcot# 260-17-1Yaptone DatuMarcot# 260-17-1Yaptone DatuMarcot# 260-17-1Yaptone DatuMarcot# 260-17-1Yaptone DatuMarcot# 260-17-1Yaptone Datu# 260-17-1# 260-17-1Yaptone Datu# 260-17-1# 260-17-1Yaptone Datu# 260-17-1# 260-17-1Yaptone Datu# 260-17-1 <td< td=""><td>Sodium Chloride</td><td>Thermo Fisher Scientific</td><td># \$64010</td></td<>	Sodium Chloride	Thermo Fisher Scientific	# \$64010
Potasiun ChloridePR1#P173GlycerolInerno Fisher Scientif4G33.1DTTIherno Fisher Scientif#D100-100.0Manganes chloride tertahydrateIherno Fisher Scientif#M87.100PMSFRP1#P20270.50.1Brilliant blue R-250RP1#B4300.50.0EDTATherno Fisher Scientif#B4300.50.0FormanideTherno Fisher Scientif#S12.13.1SDSTherno Fisher Scientif#151.21.3Yalen CyanolMarco#S00.71.1TyponeWR#151.23.1TyponeWR#151.23.1Forno SulfacMerno Fisher Scientif#161.23.1Yata ExtractScientific#161.23.1Forno sulfacFisher Scientif#161.23.1Forto sulfacFisher Scientific#146.50.1Forto sulfacFisher Scientific#145.50.1Forto sulfacFisher Scientific	Imidazole	Thermo Fisher Scientific	# O3196-500
GlycerolThermo Fisher Scientific# G33-1DTTThermo Fisher Scientific# D11000-100.0Manganese chloride tetrahydrateThermo Fisher Scientific# M87-100PMSFRPI# P20270-25.0Brilliant blue R-250RPI# B43000-50.0EDTAThermo Fisher Scientific# 6381-92-6FormamideThermo Fisher Scientific# 51-2.7SDSThermo Fisher Scientific# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TyptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrous sulfateFisher Scientific# 146-500Ferric citrateFisher Scientific# 112500Loystein free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# B1725100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-709Moric AcidRPI# 50-213-709IPTGFisher Scientific# 11800-025Ammonium persulfateRPI# 50-213-709IPTGRPI# 50-213-709IPTGFisher Scientific# 11800-025Ammonium persulfateRPI# 50-213-709IPTGFisher Scientific# 11800-025Ammonium persulfateRPI# 50-213-709IPTGFisher Scientific# 11800-025Ammonium persulfateRPI# 30-20-200.00 </td <td>Potassium Chloride</td> <td>RPI</td> <td># P2173</td>	Potassium Chloride	RPI	# P2173
DTTThermo Fisher Scientific# D11000-100.0Manganese chloride tetrahydrateThermo Fisher Scientific# M87-100PMSFRPI# P20270-25.0Brilliant blue R-250RPI# B43000-50.0EDTAThermo Fisher Scientific# 6381-92-6FormamideThermo Fisher Scientific# 57-12-7SDSThermo Fisher Scientific# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TyptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrio sulfateFisher Scientific# 146-500Ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# B1725100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-709Boric AcidRPI# 50-213-709IPTGFisher Scientific# 11800-0.25Ammonium persulfateRPI# 50-213-709Boric AcidRPI# 50-213-709IPTGFisher Scientific# 11800-0.25Ammonium persulfateRPI# 50-213-709IPTGFisher Scientific# 11800-0.25Ammonium persulfateRPI# 50-213-709IPTGFisher Scientific# 50-213-709IPTGFisher Scientific# 50-213-709IPTGFisher Scientific# 50-213-70	Glycerol	Thermo Fisher Scientific	# G33-1
Manganese chloride tetrahydrateThermo Fisher Scientific# M87-100PMSFRPI# P20270-25.0Brilliant blue R-250RPI# B43000-50.0EDTAThermo Fisher Scientific# 6381-92-6FormamideThermo Fisher Scientific# 51-12-7SDSThermo Fisher Scientific# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# 114-500Ferrous sulfateFisher Scientific# 114-500Ferric citrateFisher Scientific# 114-500Luria BrothFisher Scientific# 114-500Ferric citrateFisher Scientific# 112500Loystein free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher Scientific# 11800-0.25Ammonium persulfateRPI# AAA0090-0.25Ammonium persulfateRPI# 20500-100.0UreaThermo Fisher Scientific# 51-13-6Magnesium chlorideKanamycin monsulfate# 51-13-6Ammonium persulfateRPI# 420500-100.0UreaThermo Fisher Scientific# 51-13-6Magnesium chlorideRPI# 420500-100.0UreaThermo Fisher Scientific# 51-13-6Magnesium chlorideThermo	DTT	Thermo Fisher Scientific	# D11000-100.0
PMSFRPI# P20270-25.0Brilliant blue R-250RPI# B43000-50.0EDTAThermo Fisher Scientifie# 6381-92-6FormanideThermo Fisher Scientifie# 75-12-7SDSThermo Fisher Scientifie# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientifie# BP14262TyptoneRPI# 50213718Yeast ExtractThermo Fisher Scientifie# DF0127-07-1Ferrous sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 1146-500Lurysteine free baseFisher Scientific# 112500Lorge AcidFisher Scientific# 112500Lorge AcidRPI# 502137.09Boric AcidRPI# 502.13.709Boric AcidRPI# 502.13.709Boric AcidRPI# 4AAA108963640% Acrylamide/Bis solution, 19:1Fisher Scientific# 11800-0.25Ammonium persulfateRPI# 420500-100.0UreaThermo Fisher Scientific# 51.3-6Magnesium chlorideThermo Fisher Scientific# 51.3-6Magnesium chlorideRPI# 48000-0.25Anmonium persulfateRPI# 420500-100.0UreaThermo Fisher Scientific# 51.3-6Magnesium chlorideRPI# 8906-5Anmonium persulfateRPI# 800-5Anmonium persulfateRPI# 800-5Anmonium persulfateRPI <td>Manganese chloride tetrahydrate</td> <td>Thermo Fisher Scientific</td> <td># M87-100</td>	Manganese chloride tetrahydrate	Thermo Fisher Scientific	# M87-100
Brilliant blue R-250RPI# B43000-50.0EDTAThermo Fisher Scientific# 6381-92-6FormamideThermo Fisher Scientific# 75-12-7SDSThermo Fisher Scientific# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferriou sulfateFisher Scientific# 114-500Ferric citrateFisher Scientific# 114-500Lurygteine free baseMP Biomedicals# 522-50-7Anmonium ferric citrateFisher Scientific# 172500Lorygteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100This BaseRPI# 50-213-709Boric AcidRPI# 50-213-709Boric AcidRPI# 50-213-709IPTGFisher Scientific# BP1755100This BaseRPI# 50-213-709Boric AcidRPI# 50-213-709IPTGFisher Scientific# 140-500Timonium persulfateRPI# 50-213-709UreaRPI# 50-213-709Ammonium persulfateRPI# 50-213-709IPTGFisher Scientific# 57-13-6Magnesium chlorideRPI# 20500-100.0UreaNemo Fisher Scientific# 57-13-6Magnesium chlorideRPI# 1346-34-9Kanamy	PMSF	RPI	# P20270-25.0
EDTAThermo Fisher Scientific# 6381-92-6FormamideThermo Fisher Scientific# 75-12-7SDSThermo Fisher Scientific# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferriou sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 146-500Luria BrothFisher Scientific# 1146-500Ferric citrateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 12500Lurysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-709Boric AcidRPI# 50-213-709IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-709Boric AcidRPI# 50-213-709UreaRPI# 50-213-709Ammonium persulfateKauamycin Mono.25Ammonium persulfateRPI# 50-213-709UreaRPI# 50-213-709Magnesium chlorideKauamycin monosulfate# 50-213-709Kanamycin monosulfateRPI# 300-0.25Ammonium persulfateRPI# 3000-0.25Anamorium nonsulfate </td <td>Brilliant blue R-250</td> <td>RPI</td> <td># B43000-50.0</td>	Brilliant blue R-250	RPI	# B43000-50.0
FormanideThermo Fisher Scientific# 75-12-7SDSThermo Fisher Scientific# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrous sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 1146-500L-cysteine free baseFisher Scientific# 3522-50-7IPTGFisher Scientific# 172500IPTGFisher Scientific# 172500Boric AcidRPI# 50-213-709Boric AcidRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 118000-0.25Ammonium persulfateRPI# 1346-34-9UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideRPI# 13446-34-9Kanamycin monosulfateRPI# BP16025AnmpicillinRPI# BP16025ChloramphenicolRPI# BP16025	EDTA	Thermo Fisher Scientific	# 6381-92-6
SDSThermo Fisher Scientific# 151-21-3Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrous sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 146-500Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 118000-0.25Ammonium persulfateRPI# 420500-100.0UreaThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP165-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP176025	Formamide	Thermo Fisher Scientific	# 75-12-7
Xylene CyanolAmresco# 2650-17-1Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrous sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-709Boric AcidRPI# 4AA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 118000-0.25Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP16025ChloramphenicolRPI# BP176025	SDS	Thermo Fisher Scientific	# 151-21-3
Bromophenol BlueVWR# 115-39-9Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrous sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 3522-50-7L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# 19755100Tris BaseRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 118000-0.25Ammonium persulfateRPI# 420500-100.0UreaThermo Fisher Scientific# 13446-34-9Magnesium chlorideRPI# BP906-5AnnpicillinRPI# BP16025ChloramphenicolRPI# BP176025	Xylene Cyanol	Amresco	# 2650-17-1
Luria BrothThermo Fisher Scientific# BP14262TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrious sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 118000-0.25Ammonium persulfateRPI# 320500-100.0UreaThermo Fisher Scientific# 13446-34-9Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Bromophenol Blue	VWR	# 115-39-9
TryptoneRPI# 50213718Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferrous sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-709Hendel/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 4AA1089636UreaRPI# 18000-0.25Ammonium persulfateRPI# 420500-100.0UreaThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Luria Broth	Thermo Fisher Scientific	# BP14262
Yeast ExtractThermo Fisher Scientific# DF0127-07-1Ferricus sulfateFisher Scientific# 1146-500Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-70940% Acrylanide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# AAA1089636VereaRPI# 718000-0.25Magnesium chlorideRPI# 320500-100.0Kananycin monosulfateRPI# 31446-34-9AmpicillinRPI# BP06-5AnpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Tryptone	RPI	# 50213718
Ferrous sulfateFisher Scientific#146-500Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 118000-0.25Ammonium persulfateRPI# 420500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideRPI# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Yeast Extract	Thermo Fisher Scientific	# DF0127-07-1
Ferric citrateFisher Scientific# 3522-50-7Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# 50-213-70940% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# T18000-0.25Ammonium persulfateRPI# AA20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideRPI# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP176025	Ferrous sulfate	Fisher Scientific	# I146-500
Ammonium ferric citrateFisher Scientific# 172500L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# 118000-0.25Ammonium persulfateRPI# 118000-0.25UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP176025	Ferric citrate	Fisher Scientific	# 3522-50-7
L-cysteine free baseMP Biomedicals# 52-90-4IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# T18000-0.25Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Ammonium ferric citrate	Fisher Scientific	# I72500
IPTGFisher Scientific# BP1755100Tris BaseRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP14061TEMEDRPI# T18000-0.25Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	L-cysteine free base	MP Biomedicals	# 52-90-4
Tris BaseRPI# 50-213-709Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# T18000-0.25Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	IPTG	Fisher Scientific	# BP1755100
Boric AcidRPI# AAA108963640% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# T18000-0.25Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Tris Base	RPI	# 50-213-709
40% Acrylamide/Bis solution, 19:1Fisher ScientificBP 14061TEMEDRPI# T18000-0.25Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Boric Acid	RPI	# AAA1089636
TEMEDRPI# T18000-0.25Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	40% Acrylamide/Bis solution, 19:1	Fisher Scientific	BP 14061
Ammonium persulfateRPI# A20500-100.0UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	TEMED	RPI	# T18000-0.25
UreaThermo Fisher Scientific# 57-13-6Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Ammonium persulfate	RPI	# A20500-100.0
Magnesium chlorideThermo Fisher Scientific# 13446-34-9Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Urea	Thermo Fisher Scientific	# 57-13-6
Kanamycin monosulfateRPI# BP906-5AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Magnesium chloride	Thermo Fisher Scientific	# 13446-34-9
AmpicillinRPI# BP176025ChloramphenicolRPI# BP904-100	Kanamycin monosulfate	RPI	# BP906-5
Chloramphenicol RPI # BP904-100	Ampicillin	RPI	# BP176025
	Chloramphenicol	RPI	# BP904-100

REAGENT or RESOURCE	SOURCE	IDENTIFIER
T4 Polynucleotide Kinase	New England Biolabs	# M0201L
T4 DNA Ligase	New England Biolabs	# M0202L
DpnI	New England Biolabs	# R0176L
Phusion High Fidelity DNA Polymerase	New England Biolabs	# M0530L
ExoT	New England Biolabs	# M0265S
Sigmacote	Thermo Fisher Scientific	# SL225ML
Invitrogen SYBR Safe DNA Gel Stain	Thermo Fisher Scientific	# \$33102
[γ- ³² P]-ΑΤΡ	Perkin Elmer	# BLU502A250UC
A. halodurans Cas4	This paper	N/A
A. halodurans Cas4 E108A	This paper	N/A
A. halodurans Cas1	This paper	N/A
A. halodurans Cas2	This paper	N/A
A. halodurans Cas1 E166A	This paper	N/A
A. halodurans Cas2 a.2 (T46A, T49A, L53A, T56A, S57A)	This paper	N/A
A. halodurans Cas4 Q16A	This paper	N/A
A. halodurans Cas4 H17A	This paper	N/A
A. halodurans Cas4 F20A	This paper	N/A
A. halodurans Cas4 Q24A	This paper	N/A
A. halodurans Cas4 W34A	This paper	N/A
A. halodurans Cas4 Q44A	This paper	N/A
A. halodurans Cas4 S194A	This paper	N/A
A. halodurans Cas4 Cth	This paper	N/A
A. halodurans Cas4 Q (K206A, R207A, K210A, R211A)	This paper	N/A
Critical commercial assays	•	
Wizard SV Gel and PCR Clean-up system	Promega	# A9282
Wizard Plus SV minipreps DNA purification system	Promega	# A1460
Microspin G-25 columns	Cytiva	# 27532501
Mini Protean TGX Precast Gels 4-20 %	Biorad	# 4561096
HisPur Ni-NTA resin	Thermo Fisher Scientific	# 88223
HiTrap Heparin HP	GE Healthcare	# 17040703
Superdex 200 Increase 10/300	Cytiva	# 28990944
HiLoad 16/600 Superdex 200	GE Healthcare	# 28989335
HiLoad 16/600 Superdex 75	GE Healthcare	# 28989333
Deposited data		•
Structural models		
Cas4-Cas1-Cas2 PAM/PAM	This paper	8D3L
Cas4-Cas1-Cas2 PAM/NoPAM	This paper	8D3Q
Cas4-Cas1-Cas2 PAM/Processed	This paper	8D3M
Cas4-Cas1-Cas2 HSI	This paper	8D3P

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Cryo-EM maps	•	•
Cas4-Cas1-Cas2 PAM/PAM	This paper	EMD-27159
Cas4-Cas1-Cas2 PAM/NoPAM	This paper	EMD-27162
Cas4-Cas1-Cas2 PAM/Processed	This paper	EMD-27160
Cas4-Cas1-Cas2 HSI	This paper	EMD-27161
Cas4-Cas1-Cas2 PAM/PAM 24 bp duplex	This paper	EMD-27769
Oligonucleotides		
See Tables S1 and S2 for sequences of oligonucleotides used in this stud	у	
Recombinant DNA		
pET52b/ His ₆ Cas4	Lee et al., 2018, 2019	N/A
pET52b/ His ₆ Cas4 E108A	Lee et al., 2018, 2019	N/A
pSV272/ His ₆ -MBP-TEV Cas1	Lee et al., 2018, 2019	N/A
pSV272/ His ₆ -MBP-TEV Cas2	Lee et al., 2018, 2019	N/A
pSV272/ His ₆ -MBP-TEV Cas1 E166A	This paper	N/A
pSV272/ His ₆ -MBP-TEV Cas2 a2 (T46A, T49A, L53A, T56A, S57A)	This paper	N/A
pET52b/ His ₆ Cas4 Q16A	This paper	N/A
pET52b/ His ₆ Cas4 H17A	This paper	N/A
pET52b/ His ₆ Cas4 F20A	This paper	N/A
pET52b/ His ₆ Cas4 Q24A	This paper	N/A
pET52b/ His ₆ Cas4 W34A	This paper	N/A
pET52b/ His ₆ Cas4 Q44A	This paper	N/A
pET52b/ His ₆ Cas4 S194A	This paper	N/A
pET52b/His ₆ Cas4 Cth	This paper	N/A
pET52b/Cas4 CterHis ₆ Q (K206A, R207A, K210A, R211A)	This paper	N/A
pET-His-SUMO	Eric Underbakke Lab	N/A
pET-His-SUMO/Cas1	This paper	N/A
pACYC/sufABCDSE	This paper	N/A
Software and algorithms		
Cryosparc	Punjani et al., 2017, 2020	N/A
UCSF Chimera	Pettersen et al., 2004	N/A
ChimeraX	Goddard et al., 2018	N/A
ColabFold v. 1.0	Mirdita et al., 2022	N/A
AlphaFold v. 2.1.2	Jumper et al., 2021; Varadi et al., 2022	N/A
Phenix; Molprobity	Liebschner et al., 2019; Williams et al., 2018	N/A
Coot	Emsley et al., 2010	N/A
ImageJ	Schneider et al., 2012	N/A

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Other		
Quantifoil 300 mesh R 1.2/1.3 grids	EMS	# Q350CR1.3